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A B S T R A C T
Background
Primary postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in both developed and developing countries.
Objectives
To assess the effectiveness and safety of any intervention used for the treatment of primary PPH.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 August 2013).
Selection criteria
Randomised controlled trials comparing any interventions for the treatment of primary PPH.
Data collection and analysis
We assessed studies for eligibility and quality and extracted data independently. We contacted authors of the included studies to request
more information.
Main results
Ten randomised clinical trials (RCTs) with a total of 4052 participants fulfilled our inclusion criteria and were included in this review.
Four RCTs (1881 participants) compared misoprostol with placebo given in addition to conventional uterotonics. Adjunctive use of
misoprostol (in the dose of 600 to 1000 mcg) with simultaneous administration of additional uterotonics did not provide additional
benefit for our primary outcomes including maternal mortality (risk ratio (RR) 6.16, 95% confidence interval (CI) 0.75 to 50.85),
seriousmaternalmorbidity (RR0.34, 95%CI 0.01 to 8.31), admission to intensive care (RR0.79, 95%CI 0.30 to 2.11) or hysterectomy
(RR 0.93, 95% CI 0.16 to 5.41).
Two RCTs (1787 participants) compared 800 mcg sublingual misoprostol versus oxytocin infusion as primary PPH treatment; one
trial included women who had received prophylactic uterotonics, and the other did not. Primary outcomes did not differ between the
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two groups, although women given sublingual misoprostol were more likely to have additional blood loss of at least 1000 mL (RR
2.65, 95% CI 1.04 to 6.75). Misoprostol was associated with a significant increase in vomiting and shivering.
Two trials attempted to test the effectiveness of estrogen and tranexamic acid, respectively, but were too small for any meaningful
comparisons of pre-specified outcomes.
One study compared lower segment compression but was too small to assess impact on primary outcomes.
We did not identify any trials evaluating surgical techniques or radiological interventions for women with primary PPH unresponsive
to uterotonics and/or haemostatics.
Authors’ conclusions
Clinical trials included in the current review were not adequately powered to assess impact on the primary outcomemeasures. Compared
with misoprostol, oxytocin infusion is more effective and causes fewer side effects when used as first-line therapy for the treatment of
primary PPH. When used after prophylactic uterotonics, misoprostol and oxytocin infusion worked similarly. The review suggests that
among women who received oxytocin for the treatment of primary PPH, adjunctive use of misoprostol confers no added benefit.
The role of tranexamic acid and compression methods requires further evaluation. Furthermore, future studies should focus on the
best way to treat women who fail to respond to uterotonic therapy.
P L A I N L A N G U A G E S U M M A R Y
Treatment for excessive bleeding after childbirth
After a woman gives birth, wombmuscles contract, clamping down on the blood vessels and helping to limit bleeding when the placenta
has detached. If the muscles do not contract strongly enough, very heavy bleeding (postpartum haemorrhage) can occur, which can be
life threatening. These situations are common in resource-poor countries, and maternal mortality is about 100 times higher than in
resource-rich countries. It is a very serious problem that requires effective treatments that might avoid the use of surgery to remove the
womb (hysterectomy). This is often the last treatment option and leaves the woman unable to have more children. In most settings,
women are given a drug at the time of birth (before excessive bleeding occurs) to reduce the likelihood of excessive blood loss. However,
despite this intervention, some women bleed excessively, and this review looked to see what interventions might be used to reduce the
amount of blood lost by these women. Treatment options include drugs to increase muscles contractions (such as oxytocin, ergometrine
and prostaglandins like misoprostol), drugs to help with blood clotting (haemostatic drugs such as tranexamic acid and recombinant
activated factor VII), surgical techniques (such as tying off or blocking of the uterine artery) and radiological interventions (to assist in
blocking the main artery to the womb by using gel foams).
The review identified 10 randomised controlled trials involving 4052 women. Seven of these trials looked at a drug called misoprostol,
which is a prostaglandin and so works by increasing muscle contractions. Overall, the trials suggest that misoprostol does not work as
well as oxytocin infusion, and it has more side effects. However, oxytocin needs to be kept in a refrigerator, and so in settings where
refrigeration and infusions are not readily available, misoprostol can be used.
Other clinical trials looked into using other types of drugs or squeezing the main artery that supplies blood to the woman. The number
of women included in these studies was too small for any useful conclusions regarding their effectiveness and safety.
B A C K G R O U N D
Nearly half a million women die annually across the world from
causes related to pregnancy and childbirth (Khan 2006; WHO
2010). Approximately one-quarter of these deaths are caused by
complications of the third stage of labour, that is, excessive bleed-
ing within the first 24 hours after delivery, also known as primary
postpartum haemorrhage (PPH) (Abou Zahr 1991). In the devel-
oping world, PPH remains the leading cause of maternal death,
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accounting for one-third of maternal deaths in Asia and Africa
(Khan 2006;WHO2010). In the United Kingdom (UK), the risk
of death from obstetrical haemorrhage is about one in 100,000
deliveries (Cantwell 2011).
Physiology
The uterus is composed of a unique interlacing network of muscle
fibres known as ’myometrium’. The blood vessels that supply the
placental bed pass through this latticework of uterine muscle (
Baskett 2000). Myometrial contraction is the main driving force
for both placental separation andhaemostasis through constriction
of these blood vessels. This blood-saving mechanism is known as
the ’physiological sutures’ or ’living ligatures’ (Baskett 2000). The
physiological increase in clotting factors during labour helps to
control blood loss after separation of the placenta.
Active management of the third stage of labour has been standard
practice in many parts of the world for many years (Prendiville
1989). It is suggested that prophylactic administration of a utero-
tonic will help to reduce blood loss and blood transfusion af-
ter delivery (Begley 2011). The role of early cord clamping and
controlled cord traction in the reduction of bleeding is less clear;
although it was once thought important to deliver the placenta
quickly after uterotonic drug administration, to prevent it from
being retained (McDonald 2013), delayed cord clamping is now
favoured.
Blood loss up to 500 mL at delivery is regarded as ’physiological’.
It is part of the normal mechanism that brings the mother’s blood
parameters to their normal non-pregnant levels, and a healthy
pregnant woman can cope with it with no difficulty (Gyte 1992;
Ripley 1999).
Definition
Traditionally, primary PPH is defined as bleeding from the genital
tract of 500 mL or more in the first 24 hours following delivery of
the baby (Cunningham 1993, Abou Zahr 1991). Alternative cut-
off levels of 600 mL (Beischer 1986), 1000 mL (Burchell 1980),
1500 mL (Mousa 2002), with a substantial fall in haematocrit
or the need for blood transfusion (ACOG 1998; Combs 1991),
have also been used. Unfortunately, underestimation of blood loss
following delivery is a common problem, as visually (clinically)
assessed bleeding underestimates measured blood loss by an av-
erage of 100 to 150 mL (Pritchard 1962; Sloan 2010; Stafford
2008). Several methods have been proposed for measuring blood
loss objectively, but they are used mainly for research purposes
(Sloan 2010). In addition, women delivering by caesarean section
lose more blood on average than women who have vaginal birth;
therefore, 1000 mL is commonly used as a cutoff for significant
blood loss after caesarean section. Overall, a trend towards increas-
ing the rate of primary PPH has been seen in developed countries
(Knight 2009).
Causes and risk factors
Several factors influence PPH rates, including whether blood loss
is measured, how the third stage of labour is managed (e.g. the
provision of uterotonic, uterine massage, controlled cord trac-
tion), obstetrical interventions carried out at the time of deliv-
ery (e.g. episiotomy, mode of delivery) and characteristics of the
study population (Begley 2011; Carroli 2008). Lack of efficient
uterine contraction (uterine atony) is the most common cause of
primary PPH. Other aetiological factors include retained parts of
the placenta and vaginal or cervical tears. Uterine rupture, clotting
disorders and uterine inversion are extremely rare but often very
dramatic causes of heavy bleeding. Several investigators have at-
tempted to identify factors that may pre-dispose women to exces-
sive blood loss after delivery. Examples of risk factors include first
pregnancy (Gilbert 1987; Hall 1985), maternal obesity (Aisaka
1988), a large baby (Stones 1993), twin pregnancy (Combs 1991;
Suzuki 2012), prolonged or augmented labour (Gilbert 1987),
chorioamnionitis, pre-eclampsia, maternal anaemia and antepar-
tum haemorrhage (Wetta 2013). High multiparity does not ap-
pear to be a risk factor in high- or low-income countries, even after
control for maternal age (Drife 1997; Stones 1993; Tsu 1993).
Despite the identification of potential risk factors, primary PPH
often occurs unpredictably in low-risk women (Mousa 2008).
Complications
The most important consequences of severe PPH include death,
hypovolaemic shock, disseminated intravascular coagulopathy, re-
nal failure, hepatic failure and adult respiratory distress syndrome
(Bonnar 2000). In low-income countries, poor nutritional status,
lack of easy access to treatment and inadequate intensive care and
blood bank facilities are additional contributing factors that lead
to high morbidity and mortality rates in these countries (Khan
2006; WHO 2010). As no definition of PPH has been universally
accepted, the exact incidence of serious complications is difficult
to ascertain (Knight 2009).
Management of primary PPH
Treatment for primary PPH requires amultidisciplinary approach.
After exclusion of lower genital tract tears, in most cases, bleeding
is due to uterine atony. Uterotonics that increase the efficiency of
uterine contraction, including ergometrine and oxytocin, were in-
troduced as first-line therapy for atonic PPH in the 19th century.
Women who continue to bleed require further assessment and in-
terventions to control bleeding. These interventions may include
additional uterotonics, haemostatic drugs, surgical interventions,
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radiological embolisation and/or compression devices (Abou El
Senoun 2011).
A. Uterotonics
Ergometrine
John Stearns (Stearns 1822) was the first to emphasise the use of
ergots for PPH. Earlier, he wrote describing ergot’s action: “It ex-
pedites lingering parturition ... The pains induced by it are pe-
culiarly forcing ... In most cases you will be surprised with the
suddenness of its operation” (Stearns 1808). Moir 1932 noticed
that administration of aqueous ergot extract by mouth is associ-
ated with dramatic and vigorous uterine contractions, which were
described as the ’John Stearns effect’. In 1935, Dudley and Moir
were able to isolate the pure crystallised substance from the water-
soluble extract of ergot that was responsible for the ’John Stearns
effect’, and they called it ’ergometrine’ (Dudley 1935). The iso-
lation of a new water-soluble extract of ergot was announced al-
most simultaneously from three other centres: in America (Davis
1935), the UK (Thompson 1935) and Switzerland (Stoll 1935).
It turned out to be the same substance. The Americans called their
preparation ergonovine, and the Swiss used the name ergobasine.
Although the use of oxytocin is usually free of adverse effects, the
use of ergometrine may be associated with nausea, vomiting and
hypertension (ACOG 1998).
Oxytocin
In 1953, Vincent Du Vigneaud (Du Vigneaud 1953) identified
the structure of oxytocin and was able to synthesise the hormone.
By the 1980s, several randomised controlled trials and their meta-
analyses confirmed the effectiveness of active management of the
third stage in reducing PPH (Begley 2011). Oxytocin and er-
gometrine have traditionally formed essential components of first-
line therapy in the management of primary PPH. Ergometrine
(and the mixed drug combination of oxytocin and ergometrine)
is contraindicated in women with a history of hypertension, heart
disease, pre-eclampsia or eclampsia.
Carbetocin is a long-acting synthetic oxytocin analogue that can
be administered as a single dose either intravenously or intramus-
cularly; it produces a similar uterotonic effect as oxytocin. Intra-
venously administered carbetocin has a half-life of 40 minutes
(four to 10 times longer than oxytocin). Uterine activity persists
for 120 minutes and 60 minutes following intramuscular and in-
travenous injection, respectively (Hunter 1992). In Europe, this
drug is licenced only for prevention of uterine atony after cae-
sarean section. Carbetocin is as effective, but more expensive, than
oxytocin (Su 2007). It may have unpleasant side effects, includ-
ing headaches, tremor, hypotension, flushing, nausea, abdominal
pain, pruritus and a feeling of warmth (Rath 2009).
Prostaglandins
By the 1970s, the prostaglandin F2 alpha series was discovered
by Sune Bergstrom, among others (Bergstrom 1962). The 15-
methyl analogue of prostaglandin F2 alpha has been reported to
have a high success rate if used alone (88%) or in combination
with other uterotonic agents (95%) (Oleen 1990). Prostaglandin
administration could be associated with unpleasant side effects,
including vomiting, diarrhoea, hypertension and fever (Oleen
1990).
Misoprostol, a methyl ester synthetic analogue of natural
prostaglandin E1, is a thermo-stable, inexpensive drug that can be
used for prevention and treatment of PPH. It can be administered
orally, sublingually, buccally, vaginally or rectally. A Cochrane sys-
tematic reviewof randomised trials ofmisoprostol versus injectable
uterotonics in management of the third stage of labour suggests
that the drug is less effective than injectable uterotonics in the pre-
vention of severe PPH (blood loss ≥ 1000 mL) and has more ad-
verse effects, including nausea, vomiting and diarrhoea (Hofmeyr
2008; Tunçalp 2012).
In most cases, uterotonic drugs will control postpartum bleeding,
but if they do not, surgical intervention must be considered.
B. Haemostatic drugs
Haemostatic drugs, including tranexamic acid (As 1996) and re-
combinant activated factor VII (rFVIIa) (Moscardo 2001), have
been used for the treatment of intractable haemorrhage unrespon-
sive to first- and second-line therapies. Tranexamic acid is a sys-
temic antifibrinolytic agent that is widely used in surgery to pre-
vent clot breakdown (fibrinolysis) and therefore to reduce blood
loss. It is a simple, inexpensive drug that requires no training for
administration and can be used for prevention and treatment of
primary PPH (As 1996; Ferrer 2009; Novikova 2010). It has a
short half-life of two hours.The use of tranexamic acid may be
associated with side effects, including nausea, vomiting and diar-
rhoea.Other rare complications include hypotension, thrombosis,
blurred vision, renal cortical necrosis and retinal artery obstruc-
tion (Novikova 2010; Peitsidis 2011).
Recombinant activated factor VII (rFVIIa; Novo Nordisk A/S,
Bagsvaerd, Denmark) has also been successfully used for control-
ling life-threatening PPH. It reduces blood loss through enhance-
ment of tissue factor-dependent coagulation. It is effective in up
to 80% of cases (Alfirevic 2007) but is quite expensive. Adverse
events were observed in 2.5% of treated cases (Franchini 2010).
Of note, all adverse events were thrombotic, including deep ve-
nous thrombosis, pulmonary embolism, cerebral thrombosis and
myocardial infarction.
C. Surgical interventions
Porro (Porro 1876)was the first to describe caesarean hysterectomy
to prevent death from uterine haemorrhage. However, the tech-
nique is associated with major complications and sterility. Active
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attempts have beenmade to introduce other conservativemeasures
to avoid hysterectomy.
Uterine tamponade
Uterine packing, using several yards of wide gauze placed inside
the uterine cavity, was one of the earliest methods introduced to
achieve a tamponade effect to control primary PPH (Eastman
1950). It fell out of favour in the 1950s, as it was thought to conceal
haemorrhage and cause infection (Eastman 1950). However, this
technique re-emerged in the 1980s and 1990s after these concerns
were not confirmed (Maier 1993).
Over the past decade, active attempts have been made to intro-
duce better alternatives for uterine packing through the use of
balloon tamponade, including Foley’s catheter (De Loor 1996),
the Sengstaken-Blakemore tube (Chan 1997), the Rusch catheter
(Johanson 2001), the Bakri balloon (Bakri 1999) and the condom
catheter (Akhter 2005). After exclusion of a genital tract lacera-
tion, these procedures can be considered for control of obstetri-
cal haemorrhage secondary to uterine atony, placenta accreta and
placenta praevia. Overall, the difference between them is related
mainly to balloon volume and the presence or absence of a cav-
ity for draining blood. The overall success rate is around 80%
(Doumouchtsis 2007; Georgiou 2009). Close observation of uter-
ine size and the general condition of the woman is mandatory, as
significant bleeding may occur distal to the bulb (Alamia 1999).
Artery ligation and uterine compression sutures
Ligation of the uterine artery or its main supply (internal iliac
artery) may be considered in selected cases (AbdRabbo 1994;
Jouppila 1995). However, the latter may be technically difficult
and is successful in less than 50% of cases (Clark 1985).
Uterine compression sutures have recently been described (
B-Lynch 1997; Cho 2000; Hayman 2002; Marasinghe 2011;
Ouahba 2007; Pereira 2005; Zheng 2011). B-Lynch was the first
to describe a suture that runs through the full thickness of both
uterine walls (anterior and posterior) (B-Lynch 1997).When tied,
the suture allows tight compression of the uterine walls and stops
the bleeding (Mousa 2001). Single or multiple stitches may be
inserted at the same time and, according to the shape, they may be
called brace suture (B-Lynch 1997), simple brace (Hayman 2002)
or square sutures (Cho 2000). Although they are thought to be ef-
fective in selected cases, unexpected occlusion of the uterine cavity
with subsequent development of intrauterine synechiae (Poujade
2011; Rathat 2011) or infection (pyometra) has been reported
(Ochoa 2002). The choice of the type of surgical intervention
depends on several factors, paramount of which is the experience
of the surgeon. Other factors include parity and desire for future
children, the extent of the haemorrhage and the general condition
of the woman (Cantwell 2011).
D. Radiological embolisation
Selective radiological embolisation of the bleeding vessel may be
a therapeutic option in centres where interventional radiologists
are available and the bleeding is not life threatening (Arulkumaran
2007). In a systematic review, Doumouchtsis and colleagues eval-
uated the success rate of emergency embolisation for the control of
major PPH. They reported a success rate of 91% (Doumouchtsis
2007). The procedure has many advantages including minimal
morbidity and complication rates, shorter hospital stay and preser-
vation of fertility; it can be carried out under local anaesthesia,
and success can be verified. The procedure is not free of compli-
cations (Doumouchtsis 2007; Penninx 2010; Tseng 2011). Post-
procedure fever is the most common complication and typically
resolves within two to three days. Other complications include
feet ischaemia, bladder and rectal wall necrosis and sciatic nerve
injury (Doumouchtsis 2007). Late re-bleeding is a rare but seri-
ous problem, and repeated embolisation or hysterectomy may be
required. The use of interventional radiological techniques is lim-
ited by availability, and few centres have a 24-hour trained, skilled
team. Unlike with other procedures, an unstable patient has to be
moved to the angiography suite (Mousa 2002).
E. Non-pneumatic antishock garment (NASG) and
aortic compression device
In the 1900s, an inflatable pressure suit was developed by George
Crile (Vahedi 1995). After several modifications, it was used in the
Vietnam War for resuscitation of soldiers with traumatic injuries
(Cutler 1971). In the 1970s, the G-suit was modified into a half-
suit, which became known as MAST (military antishock trousers)
or PASG (pneumatic antishock garment). From the 1970s, theNa-
tional Aeronautics and Space Administration (NASA) contributed
to the development of a “non-pneumatic version” of the antishock
garment. This was originally used for children with haemophilia
but has since been developed into the garment known as the non-
pneumatic antishock garment (NASG) (Haggerty 1996). The
NASG is a low-technology pressure device that decreases blood
loss, restores vital signs and has the potential to reduce adverse
outcomes by helping women survive delays in receiving adequate
emergency obstetrical care. Use of this garment as a temporis-
ing measure to stabilise women awaiting transfer to higher levels
of care began in 2002 (Hensleigh 2002). Use of NASG among
women with primary PPH in low-income countries was associated
with significant reduction of measured blood loss, severe maternal
morbidities and mortality and emergency hysterectomy (Miller
2009; Ojengbede 2011).
External aortic compression is an emergency manoeuvre proposed
to reduce PPH and permit time for resuscitation and control of
bleeding. This technique involves compression of the abdominal
aorta using a strong metal spring that is cylindrical in shape and
is fixed in place by a leather belt wrapped around the waist (
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Soltan 2009). It is a cost-effective and easily applied manoeuvre
that allows satisfactory management of PPH (Soltan 2009).
Rationale for the review
The quest for fast, effective and safe interventions in cases of major
primary PPH is the focus of this review. Other relevant published
Cochrane reviews are Begley 2011, which compares active with
expectant third-stage management; Tunçalp 2012, Cotter 2001,
McDonald 2004, Su 2012, Liabsuetrakul 2007 and Oladapo
2012b, which consider the role of different prophylactic uteroton-
ics in third-stage management; Nardin 2011, which looks at the
role of umbilical vein injection in the treatment of retained pla-
centa; Oladapo 2012a, which evaluates advance community dis-
tribution of misoprostol for preventing or treating PPH; Novikova
2010, which evaluates the place of tranexamic acid for preventing
PPH and Alexander 2002, which is examining drug treatment for
secondary PPH. The current review focuses primarily on atonic
primary PPH. Management of haemorrhage due to laceration of
the genital tract is outside the scope of this review.
O B J E C T I V E S
To determine the effectiveness of any intervention used for the
treatment of primary postpartum haemorrhage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials of treatment for primary postpar-
tum haemorrhage (PPH).
Types of participants
Women after delivery following a pregnancy of at least 24 weeks’
gestation with a diagnosis of primary PPH, regardless of mode of
delivery (vaginal or caesarean section) or other aspects of third-
stagemanagement. Initially, our protocol stipulated that only stud-
ies in which primary PPH was defined as blood loss greater than
500 mL would be included. As it may be difficult to obtain an
accurate measurement of blood loss before recruitment, we ex-
panded our inclusion criteria to include trials in which PPH was
defined in one of the following ways:
• women with blood loss of 500 mL or more and/or
• women with primary PPH requiring blood transfusion and/
or blood products and/or
• women with a clinical diagnosis of primary PPH (as defined
by trialists).
Exclusion criteria
• Women with PPH with gestational age less than 24 weeks.
Types of interventions
Eligible interventions included:
• uterotonic agents that encourage uterine contractility (such
as oxytocin, ergometrine, carbetocin and prostaglandins);
• haemostatic agents that influence the clotting cascade
(tranexamic acid and recombinant activated factor VII);
• surgical interventions such as uterine packing or
intrauterine catheter insertion, artery ligation, uterine
compression sutures and/or hysterectomy;
• interventional radiology (X-ray-guided embolisation);
• non-pneumatic antishock garment (NASG) and aortic
compression device; and
• any other medical or surgical intervention.
Main comparisons included the following interventions.
• Uterotonics versus control (no intervention) or placebo.
• One uterotonic agent versus other single or multiple
uterotonic drugs.
• Haemostatic drugs versus other treatment, or versus control
or placebo.
• Uterine packing or balloon tamponade (e.g. Foley,
hydrostatic catheter) versus other treatment, or versus control or
placebo.
• Uterine compression sutures (e.g. brace, square) versus
other treatment, or versus control or placebo.
• Vessel ligation versus other treatment, or versus control or
placebo.
• Hysterectomy versus other treatment, or versus control or
placebo.
• Radiological embolisation versus other treatment, or versus
control or placebo.
• Non-pneumatic antishock garment (NASG) and aortic
compression device versus other treatment, or versus control or
placebo.
• Any other medical or surgical intervention used for
treatment of primary PPH versus other treatment or versus
control or placebo.
Control group is defined as a group of participants randomly as-
signed to not receiving the active medication or factor under study
and thereby serving as a comparison group for the intervention.
Placebo group is defined as a group of women randomly assigned
to receive a dummy treatment.
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Treatment for primary PPH requires amultidisciplinary approach.
Anymeasures and/or drug therapy taken as part of the initial treat-
ment is considered first-line therapy. In most cases, this includes
resuscitation measures, exclusion of genital tract laceration, check-
ing of the placenta and the use of uterotonics. Women who con-
tinue to bleed require further assessment and interventions to con-
trol the bleeding, commonly referred to as second-line therapy.
This may include additional uterotonics, haemostatic drugs, sur-
gical interventions, radiological embolisation and/or compression
devices (Abou El Senoun 2011).
Types of outcome measures
Primary outcomes
• Maternal mortality.
• Serious maternal morbidity (renal or respiratory failure,
cardiac arrest or multiple-organ failure).
• Admission to intensive care.
• Hysterectomy (provided it is not part of the intervention
under investigation).
Secondary outcomes
Outcome measures related to blood loss
• Number of women with total blood loss 500 mL or more
after enrolment.
• Number of women with total blood loss 1000 mL or more
after enrolment.
• Mean blood loss (mL).
• Blood transfusion.
• Duration from randomisation to cessation of bleeding or
obtaining satisfactory response (as determined by the trialist).
• Post-randomisation additional uterotonic used to control
bleeding.
• Post-randomisation surgical intervention used to control
bleeding.
Side effects
Side effects of therapy or intervention (such as headache, vomiting,
injuries). These will be related to the type of intervention under
investigation.
Other
• Days in hospital.
• Iron therapy in the puerperium.
• Secondary PPH (vaginal bleeding after 24 hours to 42 days
following delivery).
• Interventions to control secondary PPH (medical, surgical
or both).
• Hospital readmission and number of days in hospital.
• Failure to continue breastfeeding at discharge from hospital
and at 42 days of delivery.
• Economic outcomes.
• Maternal dissatisfaction with therapy.
• Quality of life, including physiological activity and social
and emotional changes.
Assessment of blood loss could vary between trials. It is expected
that measurement of blood and blood clots in jars and weighing
of linen are likely to be more precise than clinical judgement. The
latter is known to underestimate blood loss (Pritchard 1962). The
way of reporting the amount of loss as ’greater than’ or ’greater
than or equal to’ a certain cutoff level (e.g. greater than 500 mL
or greater than or equal to 500 mL) may affect the total reported
amount of blood loss, especially when this amount is estimated. It
is expected that trials evaluating uterotonic or haemostatic drugs
may use other uterotonics to maintain contractions of the uterus
after randomisation. Also, it should be taken into consideration
that hysterectomy could be a method of intervention or co-inter-
vention, as well as an outcome measure.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 Au-
gust 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.¬
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We did not apply any language restrictions.
Data collection and analysis
For methods used in assessing the trials identified in the previous
version of this review, see Mousa 2007.
For this update (2014), we used the following methods when
assessing trials identified by the search.
Selection of studies
Two review authors (HAM and GAES or HAM and HS) inde-
pendently assessed for inclusion all potential studies identified as a
result of the search strategy.We resolved any disagreement through
discussion and consultation with ZA.
Data extraction and management
HAM designed a special data extraction form. For eligible studies,
at least two review authors (HAM and GAES or HAM and HS)
extracted data using the agreed form. We resolved any discrepan-
cies through discussion and consultation with ZA.
HAM and GAES entered data into Review Manager software (
RevMan 2012) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
In addition to the main outcomes, we systematically extracted the
following data for each study.
• Trial entry criteria (specific inclusion and exclusion criteria).
• Exclusions and missing data after randomisation.
• Mode of delivery.
• Management of the third stage of labour.
• Duration and technique of assessment of blood loss.
Assessment of risk of bias in included studies
HAM and HS independently assessed risk of bias for each study
using the criteria outlined in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Any disagreement was
resolved by discussion with ZA.
(1) Random sequence generation (checking for possible
selection bias)
We have described for each included study the method used to
generate the allocation sequence in sufficient detail to allow an
assessment of whether it should produce comparable groups.
We have assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We have described for each included study in sufficient detail the
method used to conceal the allocation sequence and have deter-
mined whether intervention allocation could have been foreseen
in advance of or during recruitment, or changed after assignment.
We have assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth); or
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We have described for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. Studies were judged at
low risk of bias if they were blinded or if we judged that the lack of
blinding could not have affected the results. Blinding was assessed
separately for different outcomes or classes of outcomes.
We have assessed the methods as:
• low, high or unclear risk of bias for participants; and
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We have described for each included study the methods used, if
any, to blind outcome assessors from knowledge of which inter-
vention a participant received. We assessed blinding separately for
different outcomes or classes of outcomes.
We have assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We have described for each included study, and for each outcome
or class of outcomes, the completeness of data, including attrition
and exclusions from the analysis. We have stated whether attrition
and exclusions were reported, the numbers included in the anal-
ysis at each stage (compared with the total of randomly assigned
participants), reasons for attrition or exclusion where reported and
whether missing data were balanced across groups or were related
to outcomes. We have contacted authors regarding published data
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and to request any missing outcome data that was included in our
analysis.
We have assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation); or
• unclear risk of bias.
(5) Selective reporting bias
We have described for each included study how we investigated
the possibility of selective outcome reporting bias and what we
have found.
We have assessed the methods as:
• low risk of bias (when it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (when not all of the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so cannot be used; study failed to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias.
(6) Other sources of bias
Wehave described for each included study any important concerns
that we have about other possible sources of bias.
We have assessed whether each study was free of other problems
that could put it at risk of bias.
• Low risk of other bias.
• High risk of other bias.
• Unclear whether there is risk of other bias.
(7) Overall risk of bias
We have made explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to the items listed above, we have assessed the likely
magnitude and direction of the bias, and whether we consider it
likely to impact the findings.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented the results as summary risk
ratios with 95% confidence intervals.
Continuous data
For continuous data, we used themean difference if outcomeswere
measured in the sameway between trials.We used the standardised
mean difference to combine trials thatmeasured the same outcome
but used different methods.
Unit of analysis issues
Cluster-randomised trials
No cluster-randomised trials were identified for inclusion. In the
future, if eligible for inclusion, we will include cluster-randomised
trials in the analyses, along with individually randomised trials.
We will adjust sample sizes using the methods described in the
Cochrane Handbook for Systematic Reviews of Interventions (Section
16.3.4) based on an estimate of the intracluster correlation coeffi-
cient (ICC) derived from the trial (if possible), from a similar trial
or from a study of a similar population. If we use ICCs from other
sources, we will report this and will conduct sensitivity analyses to
investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable
to combine the results from both if little heterogeneity is evident
between the study designs and if interaction between the effect of
the intervention and the choice of randomisation unit is consid-
ered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and will perform a (sensitivity or subgroup) analysis to investigate
the effects of the
randomisation unit.
Cross-over trials
We considered cross-over designs inappropriate for this review
question.
Dealing with missing data
For included studies, levels of attrition were noted. The impact
of including studies with high levels of missing data in the overall
assessment of treatment effect was explored by using sensitivity
analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis (i.e. we have included in the analyses all
participants randomly assigned to each group). The denominator
for each outcome in each trial was the number randomly assigned
minus any participants whose outcomes are known to be missing.
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Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
Tau², I² and Chi² statistics. We regarded heterogeneity as substan-
tial if I² was greater than 30% and either Tau² was greater than
zero or a low P value (less than 0.10) was obtained in the Chi² test
for heterogeneity.
Assessment of reporting biases
We planned to assess reporting biases if 10 or more studies were
included in the meta-analysis. In this update (2014), no meta-
analysis included 10 or more studies. In future updates, if more
studies are included, we will investigate reporting biases (such as
publication bias) using funnel plots. We will visually assess funnel
plot asymmetry.
Data synthesis
We have carried out statistical analysis using the Review Manager
software (RevMan 2012). We used fixed-effect meta-analysis for
combining data in cases where it is reasonable to assume that stud-
ies are estimating the same underlying treatment effect, that is,
when trials are examining the same intervention, and the trials’
populations and methods are judged sufficiently similar. If clinical
heterogeneity is sufficient to expect that underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
was detected, we used random-effects meta-analysis to produce
an overall summary if an average treatment effect across trials was
considered clinically meaningful. The random-effects summary
was to be treated as the average range of possible treatment effects,
and we planned to discuss the clinical implications of treatment
effects differing between trials. If the average treatment effect was
not clinically meaningful, we did not combine trials.
If we used random-effects analyses, results were presented as the
average treatment effect with 95% confidence intervals and esti-
mates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
We have carried out subgroup analyses according to route of ad-
ministration and dose of the drug used for misoprostol trials a
priori, irrespective of heterogeneity.
In future updates, with the addition of new trials, if we identify
substantial heterogeneity, we plan to investigate it further using
the following subgroup analyses.
• Mode of delivery (caesarean versus vaginal delivery).
• Setting (hospital versus community).
All primary outcome measures will be used in subgroup analyses.
We plan to assess subgroup differences by using interaction tests
available within RevMan (RevMan 2012). We will report the re-
sults of subgroup analyses by quoting theChi² statistic and P value,
as well as the interaction test I² value.
In the presence of significant heterogeneity (I² > 30%), we will
use random-effects.
Sensitivity analysis
Weplanned to carry out sensitivity analyses to explore the effect on
trial quality as assessed by concealment of allocation, high attrition
rates or both, with poor-quality studies excluded from the analyses
to assess whether this made any difference to the overall result.
Poor quality was defined as studies at high risk of bias for allocation
concealment and/or incomplete outcome data.
R E S U L T S
Description of studies
Included studies
Ten randomised clinical trials (RCTs) with a total of 4060 par-
ticipants fulfilled our inclusion criteria and were included in this
review
Uterotonic trials
Eight uterotonic studies were identified and considered for inclu-
sion in this review. Of these, one was excluded (Takagi 1976) be-
cause the trial included women with blood loss less than 500 mL
and the trial report did not allow analysis based on treatment allo-
cation (’intention to treat’). Sevenmisoprostol trials were included
in the review. Four placebo-controlled trials compared misopros-
tol (at doses of 600 to 1000 mcg) versus placebo (1881 partici-
pants) among women receiving conventional uterotonics for pri-
mary postpartum haemorrhage (PPH) treatment (Hofmeyr 2004;
Walraven 2004; Widmer 2010; Zuberi 2008). The main objec-
tive of these studies was to assess the effectiveness of the randomly
selected drug to result in fewer women having additional blood
loss of 500 mL of more. Lokugamage 2001 (64 participants) com-
pared rectally administered misoprostol (800 mcg) versus oxyto-
cics (combined syntometrine and oxytocin infusion) for the treat-
ment of primary PPH, defined as blood loss greater than 500 mL.
The main objective of the study was to assess the effectiveness of
the randomly selected drug to stop PPH within 20 minutes. The
Blum 2010 and Winikoff 2010 trials (1787 participants) com-
pared sublingual misoprostol (800 mcg) versus oxytocin infusion
(40 IU infusion) for the treatment of primary PPH among women
who had a vaginal delivery with clinically diagnosed or measured
blood loss of 700 mL or more within the first hour of delivery. The
main objective of these studies was to assess the effectiveness of
the randomly selected drug to stop PPH within 20 minutes and/
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or to result in additional blood loss of at least 300 mL. The latter
was restricted to women who had received prophylactic oxytocin
during the second or third stage of labour.
Haemostatic trials
Ducloy-Bouthors 2011 (144 participants) evaluated the place of
intravenous tranexamic acid (loading dose 4 g intravenously over
one hour, then infusion of 1 g/hour over six hours) among women
with primary PPH, defined as measured blood loss of more than
800 mL, following vaginal delivery. All participants with PPH >
500 mL were managed according to French practice guidelines:
bladder catheter,manual removal of retained placenta, genital tract
examination, uterine exploration and oxytocin (30 U/30 min),
followed, and if these procedures were inefficacious, sulprostone
was administered (500 µg in one hour) with no procoagulant
treatment. Patients with PPH > 800 mL were included in the
study. Immediately after inclusion, participants were randomly
assigned to receive tranexamic acid (tranexamic acid group) or no
antifibrinolytic treatment (control group). The main objective of
the study was to assess the effect of randomly assigned tranexamic
acid administration on blood loss at 30 minutes, two hours and
six hours of administration.
Other drug therapy trials
Zhou 2006 (112 participants) assessed the additional benefit of
estrogen adjuvant therapy (4 mg estradiol benzoate injected in-
tramuscularly) for the amount of blood loss at two and 24 hours
among women with primary PPH. 4 mg estradiol benzoate in-
jected intramuscularly with routine management when bleeding
exceeded 500 mL versus routine management only for the control
group. Routine management of the control group was described
as ’uterine massage and uterotonics administration’ and included
’20 U cervical muscle injection to contract the uterus; 20 U intra-
venous drip to contract the uterus’. In case of the cervical muscles
not restoring, injection or intravenous drip did not exceed 80 U.
Surgical trials
Chantrapitak 2009 (64 participants) assessed the amount of blood
loss at two hours after randomly assigning women with primary
PPH (defined as blood loss 500 mL or more) to lower uterine
segment compression in addition to conventional therapy for pri-
mary PPH versus conventional therapy alone.
Wedidnot identify any trials related touterine tamponade, uterine
compression suturing techniques, artery ligations or radiological
interventions.
For further details of included studies, see table of Characteristics
of included studies.
Excluded studies
For details of excluded studies, see table of Characteristics of
excluded studies.
Risk of bias in included studies
Please see Figure 1 and Figure 2 for summary of risk of bias assess-
ments.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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The Lokugamage 2001 trial compared misoprostol (800 mcg rec-
tal) versus syntometrine combined with oxytocin infusion for
treatment of PPH. The authors described clearly the random gen-
eration method and allocation concealment using consecutively
numbered, sealed, opaque envelopes. It was a single-blinded study,
as obstetricians were aware of the type of drug given, although
women and midwives were not. The trial authors indicated that
single blinding was used mainly for safety “to prevent over-dosage
and to know what had been given in case of need of additional
drugs”. No description was provided of the method of measure-
ment of blood loss or the management of the third stage of labour.
The authors have been contacted to request more information.
Post-randomisationwithdrawal of onewoman (1/32)was reported
in the misoprostol arm. The trial was prone to assessment bias,
as physicians were aware of the treatment given. Generalisation
of the results (external validity) is somewhat limited because ef-
fectiveness outcomes such as ’treatment failure’ were susceptible
to biased ascertainment. Furthermore, the authors performed an
interim analysis after 12 months (30 recruited women), and it
is unclear whether this information was shared with the clini-
cians participating in the trial. Therefore, one cannot rule out the
possibility that postrandomisation management and outcome as-
sessment were influenced by knowledge of interim results. The
study was terminated after an interim analysis revealed an 80%
difference between the two treatment arms for the pre-specified
outcome measure (effectiveness at stopping PPH within 20 min-
utes of trial drugs’ administration). Only three outcome measures
were adequately reported (hysterectomy, persistent vaginal bleed-
ing following randomisation, medical and surgical co-interven-
tions). Maternal death was not reported as an outcome. Other
reported outcome measures included blood transfusion, length of
inpatient stay and drug side effects. However, they were reported
as “P value of significance” with no numbers or percentages. No
long-term outcome data were presented.
TheWalraven 2004 andHofmeyr 2004 trials were double-blinded
studies that compared misoprostol (600 mcg in Walraven and
1000mcg inHofmeyr, delivered bymultiple routes) versus placebo
when used as an adjunct to standard uterotonics for the treatment
of primary PPH. However, the authors of the former trial believed
that blinding may have been compromised by differences in the
size of the misoprostol tablets and the placebo. Both trials used ac-
tive management of the third stage of labour and measured blood
loss after administration of conventional oxytocics for primary
PPH treatment and the trial drug. In Hofmeyr 2004, six of 244
data sheets did not include pack numbers and could not be in-
cluded in the analysis. In the Walraven 2004 trial, no withdrawals
after enrolment were reported. No long-term outcome data were
presented.
TheZuberi 2008 trial was amulti-centre double-blind randomised
controlled study that compared sublingual misoprostol (600 mcg)
versus placebo when used as an adjunct to standard uterotonics
for the treatment of primary PPH. Blinding and allocation con-
cealment were adequate, and participants were randomly assigned
in blocks of 10, using a computer-generated random sequence.
Placebo tablets were identical in shape, colour, weight, feel and
taste to misoprostol tablets. The study was powered to recruit
900 participants; however, investigators managed to recruit only
61 participants and reported results for 59 of them. The primary
outcome measure was measured blood loss of 500 mL or more
after treatment. Authors indicated that accurate use of the scales
for assessment of blood loss proved difficult. Therefore, volume of
blood was not analysed; instead measurement according to read-
ing of the blood collection device was recorded and analysed. No
long-term outcome data were presented.
The Widmer 2010 trial was a multicentre double-blind ran-
domised controlled study that compared sublingual misoprostol
(600 mcg) versus placebo when used as an adjunct to standard
uterotonics for the treatment of primary PPH. Investigators used
computer-generated randomisation sequence in blocks of six and
eight, stratified by country. Overall, blinding and allocation con-
cealment were adequate. Placebo tablets were identical in shape,
colour, weight, feel and taste to misoprostol tablets. A total of
1422 women were recruited to the study, three women did not
receive interventions and five women were lost to follow-up at 90
minutes, as blood loss was not recorded. The study was powered
to measure impact on blood loss. Methods of blood collection and
measurement varied between centres. However, trial authors in-
dicated that some of the methods used had been previously eval-
uated in the World Health Organization trial of misoprostol for
the prevention of PPH (Gülmezoglu 2001). Both groups received
standard uterotonics for the treatment of primary PPH. No long-
term outcome data were presented.
The Blum 2010 and Winikoff 2010 trials were double-blind ran-
domised controlled trials that compared sublingual misoprostol
(800 mcg) versus oxytocin infusion (40 IU in one 1000 mL of
saline over 15minutes). Both described clearly theirmethods of al-
location concealment and blinding and used similar inclusion and
exclusion criteria. Placebo tablets were identical in shape, colour,
weight, feel and taste to misoprostol tablets. However, the latter
trial included only participants for whom oxytocic drugs were not
administered during the second and third stages of labour. They
used cessation of active bleeding within 20 minutes after initial
treatment and additional blood loss of 300 mL or more as primary
end points and reported outcomes in 100% of cases. No long-
term outcome data were reported.
The Ducloy-Bouthors 2011 trial was an open-label randomised,
controlled study. It was liable to selection and performance bias.
Partial blinding was achieved, as obstetricians, midwives and par-
ticipants were not aware of interventions used. However, anaes-
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thetists were aware of the intervention and were responsible for
randomisation and administration of the trial drug. It is unclear
how the allocated intervention was concealed, as intravenous in-
fusion would be visible to all. Investigators recruited 152 partici-
pants, but one was excluded, as it was found later that she did not
fulfil the inclusion criteria. Protocol violations were reported for
seven women (five in the tranexamic acid group and two in the
control group), and the analysis reported on 144 participants (72
participants in each group). The study was not powered to mea-
sure any of our primary outcome measures. Investigators reported
few long-term outcome data.
The Zhou 2006 trial was a randomised controlled study in which
women were randomly assigned to conventional therapy versus
estrogen adjuvant therapy in addition to conventional therapy.
No description of methods of randomisation and blinding was
provided. The study was underpowered to measure any impact
on primary outcome measures. Investigators reported impact of
outcome on blood loss and hysterectomy. However, the method
used for measurement of blood loss was not described.
The Chantrapitak 2009 trial was a randomised controlled study in
which women were randomly assigned to lower uterine segment
compression in addition to conventional therapy or conventional
therapy only. Authorswere contacted to clarify randomisation, and
they have indicated that it occurred through random generation
using opaque concealed envelopes. However, the study is prone to
concealment bias, as clinicians were aware of interventions used.
The trial was underpowered to measure impact on primary out-
come measures.
Effects of interventions
Misoprostol (any route) versus placebo or no
additional treatment given to women simultaneously
treated with conventional uterotonics (four trials,
comparison 1)
Sublingual misoprostol at a dose of 600 mcg was used by Zuberi
2008 and Widmer 2010 (total of 1483 women), in addition
to conventional uterotonics, among women treated for primary
PPH. A total dose of 600 mcg (200 mcg oral and 400 mcg sublin-
gual) misoprostol was used simultaneously inWalraven 2004 (160
participants), and Hofmeyr 2004 (238 participants) used 1000
mcg misoprostol simultaneously (200 mcg oral, 400 mcg sublin-
gual and 400 mcg rectal).
Primary outcomes
Comparedwith placebo,misoprostol conferred no additional ben-
efit in terms of reduction in the rate of maternal mortality (risk ra-
tio (RR) 6.16, 95% confidence interval (CI) 0.75 to 50.85; 5/930
versus 0/951; Analysis 1.1) and hysterectomy (average RR 0.93,
95% CI 0.16 to 5.41; random-effects, Tau² = 0.83, I² = 33%; 5/
930 versus 5/951; Analysis 1.4). Only Widmer 2010 and Zuberi
2008 reported serious maternal morbidity (RR 0.34, 95%CI 0.01
to 8.31; 0/734 versus 1/749; Analysis 1.2) and admission to the
intensive care unit (RR 0.79, 95% CI 0.30 to 2.11; 7/734 versus
9/749; Analysis 1.3).
Secondary outcomes
Compared with placebo, misoprostol administered in addition to
conventional uterotonics had no significant impact on blood loss
of at least 500 mL (RR 0.89, 95% CI 0.71 to 1.12; 121/930
versus 138/950; Analysis 1.6), blood loss of at least 1000 mL (RR
0.88, 95% CI 0.42 to 1.86; 12/930 versus 14/950; Analysis 1.8)
or blood transfusion (RR 0.95, 95% CI 0.77 to 1.17; 139/928
versus 150/949; Analysis 1.7).
Side effects
Compared with placebo, misoprostol intake by any route was as-
sociated with a significant increase in vomiting (RR 1.84, 95%
CI 1.16 to 2.95; Analysis 1.18), shivering (average RR 2.25, 95%
CI 1.76 to 2.88; heterogeneity: Tau² = 0.02; Chi² = 4.71, df = 3
(P = 0.19); I² = 36%; Analysis 1.23), maternal pyrexia of at least
38°C (RR 3.12, 95% CI 2.66 to 3.67; Analysis 1.20) and mater-
nal pyrexia of 40°C or more (RR 13.58, 95% CI 4.93 to 37.44;
Analysis 1.21).
Misoprostol versus other uterotonics given to women
who have not received any conventional uterotonic
therapy (three trials, comparisons 2 and 3)
Sublingual misoprostol (800 mcg) was compared with oxytocin
infusion (40 IU) in two trials (Blum 2010; Winikoff 2010; 1787
women total). The latterwas restricted towomenwhohad received
prophylactic oxytocin during the second or third stage of labour.
Lokugamage 2001 compared rectal misoprostol (800 mcg) with a
combination of oxytocin infusion and syntometrine (64 women).
Primary outcomes
In the Blum 2010 and Winikoff 2010 trials, no significant differ-
ences were noted between the two groups for any of the primary
outcomes: maternal mortality (RR 0.99, 95% CI 0.06 to 15.74;
Analysis 2.1), hysterectomy (RR 1.98, 95% CI 0.36 to 10.72; 4/
895 versus 2/892; Analysis 2.4), admission to intensive care unit
(RR 0.33, 95%CI 0.01 to 8.06; 0/895 versus 1/892; Analysis 2.3)
and serious maternal morbidity (RR 0.33, 95% CI 0.01 to 8.06;
0/895 versus 1/892; Analysis 2.2).
In Lokugamage 2001, the rate of hysterectomy did not differ be-
tween the two groups (RR 0.33, 95% CI 0.01, 7.89; 0/32 versus
1/32; Analysis 3.1). However, the authors did not report rates of
maternal morbidity, mortality or admission to the intensive care
unit.
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Secondary outcome measures
Compared with oxytocin infusion, sublingual misoprostol use was
associated with a significant increase in the number of women
who had blood loss of at least 1000 mL (RR 2.65, 95% CI 1.04
to 6.75; Analysis 2.7) and blood transfusion (RR 1.47, 95% CI
1.02 to 2.14; Analysis 2.8). However, no significant differences
were associated with blood loss of at least 500 mL (average RR
1.51, 95% CI 01.14 to 2.00; heterogeneity: Chi² = 8.54, df = 1
(P = 0.003); I² = 88%; Analysis 2.5) and postrandomisation use
of additional uterotonics to control bleeding (average RR 1.30,
95% CI 0.57 to 2.94; random-effects, Tau² = 0.30, I² = 88%;
Analysis 2.10, analysed using a random-effects model because of
substantial heterogeneity). No significant differences were noted
between the two groups regarding the number of women who
required examination under anaesthesia, bimanual compression
or surgical intervention to control bleeding.
The Lokugamage 2001 trial found that rectal misoprostol (800
mcg) was more effective than combined oxytocin and syn-
tometrine in decreasing the need for additional uterotonics (RR
0.18, 95% CI 0.04, 0.76; Analysis 3.3). No significant differences
in any other pre-specified secondary outcomes were reported.
Side effects
Sublingual misoprostol use in 800 mcg was consistently associated
with significantly higher rates of prostaglandin-related side effects
such as vomiting and shivering.
Estrogen adjuvant therapy trials (one trial,
comparison 4)
Estrogen therapy (4 mg estradiol benzoate injected intramuscu-
larly) in addition to conventional PPH treatment was evaluated in
one single-centre trial (Zhou 2006, 112 women). 4 mg estradiol
benzoate was injected intramuscularly when routine management
was ineffective and bleeding exceeded 500mL versus routineman-
agement only. Management of the control group was described
as ’uterine massage and uterotonics administration’ and included
’20 U cervical muscle injection to contract the uterus; 20 U intra-
venous drip to contract the uterus. In case of the cervical muscles
not restoring, injection or intravenous drip did not exceed 80 U.
Where rate of blood loss exceeded 2000 mL, hysterectomy was
performed’.
Primary outcomes
Three women in the control group and no women in the estrogen
group required hysterectomy (RR 0.16, 95% CI 0.01 to 3.11;
Analysis 4.1).
Secondary outcomes
We have included two additional measures to assess blood loss, as
authors did not report any of our pre-specified secondary outcome
measures. The authors reported a significant reduction in blood
loss within two hours (-274.90 mL mean difference (MD), 95%
CI -384.72 to -165.08 mL; Analysis 4.2) and between two and
24 hours from intervention (-50.70 mL MD, 95% CI -83.07 to
-18.33 mL; Analysis 4.3).
Tranexamic acid (one trial, comparison 5)
Ducloy-Bouthors 2011 is the only placebo-controlled trial of
tranexamic acid (144 women).
Primary outcomes
No maternal deaths were reported in the study population. No
significant difference was noted between the two groups regarding
serious maternal morbidity (RR 0.33, 95% CI 0.01 to 8.05; 0/
72 versus 1/72; Analysis 5.2), admission to the intensive care unit
(RR 0.60, 95% CI 0.15 to 2.42; 3/72 versus 5/72; Analysis 5.3)
and hysterectomy (RR 0.33, 95% CI 0.01 to 8.05; 0/72 versus 1/
72; Analysis 5.4).
Secondary outcomes
No significant differences were observed in any of the pre-specified
secondary outcome measures between women with primary PPH
treated with tranexamic acid and those given placebo.
Side effects
Nausea was common with tranexamic acid administration (RR
11.00, 95% CI 1.46 to 82.99; Analysis 5.18). Three cases of deep
vein thrombosis were reported in the study population (two in the
tranexamic acid group and one in the control group; RR 2.00,
95% CI 0.19 to 21.57; Analysis 5.21).
Lower uterine segment compression versus no
compression (one trial, comparison 6)
Chantrapitak 2009 compared lower uterine segment compression
versus no intervention (64 women).
Primary outcomes
No maternal death, admission to the intensive care unit, seri-
ous maternal morbidity or hysterectomy was reported in the two
groups.
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Secondary outcomes
The number of women who had blood loss of at least 500 mL
was significantly lower among women who had lower segment
compression (RR 0.13, 95% CI 0.02 to 0.94; Analysis 6.4). How-
ever, no difference was observed between the two groups regard-
ing mean blood loss (-105.00 mL MD, 95% CI -262.00 to 52
mL; Analysis 6.6), rate of blood transfusion (RR 2.33, 95% CI
0.66 to 8.23; Analysis 6.7), number of women with blood loss of
at least 1000 mL (RR 0.20, 95% CI 0.01 to 4.01; Analysis 6.5)
and number who required surgical co-intervention to control the
bleeding (no events in either group, so not estimable) (Analysis
6.8).
D I S C U S S I O N
Summary of main results
The current review evaluated 10 clinical trials that fulfilled our in-
clusion criteria. None was adequately powered to address our pri-
mary outcome measures. Seven uterotonics trials evaluated the use
of misoprostol for the treatment of primary PPH. Data from this
review show that when misoprostol was compared with placebo
(four clinical trials), intravenous oxytocin (two trials) or combined
oxytocin and ergometrine (one trial), no statistically significant dif-
ferences were seen in clinically important outcomes including ma-
ternal mortality, serious maternal morbidity, admission to inten-
sive care andhysterectomy. Secondary outcomes, such as blood loss
greater than 1000 mL and use of additional uterotonics, favoured
intravenous oxytocin over misoprostol. The review suggests that
conventional primary PPH treatment with intravenous oxytocin
should be recommended as the more effective treatment.
The occurrence of five maternal deaths in the group of studies
comparing misoprostol versus placebo is unexpected (5/930 ver-
sus 0/930; RR 6.16; 95% CI 0.75 to 50.85). This prompted
Hofmeyr and colleagues to examine the frequency of maternal
deaths among 40,000 participants in 46 clinical trials of misopros-
tol used for the prevention or treatment of PPH (Hofmeyr 2009).
Of 11maternal deaths reported in five clinical trials, eight occurred
in women receiving misoprostol (odds ratio 2.49, 95% CI 0.67
to 8.13; Hofmeyr 2009). Subsequent trials comparing sublingual
misoprostol versus intravenous oxytocin for treatment of primary
PPH (Blum 2010; Winikoff 2010) have been more reassuring,
with one maternal death reported in each group (1/895 versus
1/895; RR 0.99, 95% CI 0.06 to 15.74). Furthermore, another
recent randomised trial comparing misoprostol versus placebo for
PPH prevention reported no maternal deaths (Mobeen 2011).
Tranexamic acid has been used for the prevention of haemorrhage
for quite some time (CRASH-2 trial collaborators 2010; Ferrer
2009;Novikova 2010; Peitsidis 2011), butDucloy-Bouthors 2011
was the first published randomised trial that examined the use of
tranexamic acid to treat primary PPH. The study is underpow-
ered to assess any impact on pre-specified primary outcome mea-
sures. The Zhou 2006 trial of estrogen adjuvant therapy was not
big enough to evaluate the impact on primary and secondary out-
comes. In the absence of any pharmacological studies to support
this current approach, it is sensible to avoid any estrogen therapy
for PPH, especially as risk of deep vein thrombosis is increased in
the immediate postpartum period.
Chantrapitak 2009 described twonew techniques to control blood
loss through transabdominal compression of the lower uterine
segment. These techniques appear simple and safe, do not require
special skills and have no major side effects. Unfortunately, the
authors did not specify which technique they used during the trial
period. Lower uterine segment compression was associated with
a modest reduction in mean blood loss and blood loss of at least
500 mL. The method warrants further evaluation, as it could be of
considerable benefit in the management of women who develop
primary PPH following home birth and require hospital transfer
for further management.
We focused on four parameters to evaluate the impact of PPH
treatments on postrandomisation blood loss: (1) blood loss of at
least 500 mL; (2) blood loss of at least 1000 mL; (3) blood trans-
fusion and (4) mean blood loss after enrolment. In this regard,
misoprostol provided no additional benefit when compared with
placebo when given to women simultaneously treated with con-
ventional uterotonics. Misoprostol was evaluated as an effective
and easy to administer alternative to intravenous oxytocin as first-
line therapy for the treatment of primary PPH in two other trials
(Blum 2010; Winikoff 2010). Compared with 40 IU oxytocin
infusion, 800 mcg sublingual misoprostol was associated with a
significant increase in the number of women who had blood loss
of at least 1000 mL (RR 2.65, 95% CI 1.04 to 6.75), blood trans-
fusion (RR 1.47, 95% CI 1.02 to 2.14) and mean blood loss (mL)
(MD 44.86, 95% CI 26.50, 63.22). Therefore, where available,
oxytocin infusion should be recommended as first-line treatment
for primary PPH. Lack of significant differences in primary out-
comes suggests that, when oxytocin infusion is not available, sub-
lingual misoprostol may serve as a valid alternative for providers
seeking a uterotonic therapy for their patients. No significant dif-
ference was reported between tranexamic acid and placebo in the
Ducloy-Bouthors 2011 study in terms of women who had blood
loss of at least 500 mL or at least 1000 mL. This is consistent
with the results of two systematic reviews (Ferrer 2009; Novikova
2010) that evaluated the use of tranexamic acid for the prevention
of PPH.
Agreements and disagreements with other
studies or reviews
Several potential reasonsmay explainwhymisoprostol randomised
trials have not confirmed optimistic preliminary results from ob-
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servational studies (Abdel-Aleem 2001; Adekanmi 2001; O’Brien
1998; Oboro 2003). In previous reports, blood loss was subjec-
tively assessed, but in the seven trials included in this review, blood
loss was measured objectively. This is particularly important, as
lack of blinding in previous studies may have affected the percep-
tion of effectiveness. The pharmacokinetics of misoprostol may
also be a contributing factor: Variation in the route and dose of
administration may result in significant variation in plasma ther-
apeutic levels of the drug. Current evidence suggests that the oral
route provides the advantage of rapid onset of action, although
the vaginal and rectal routes confer the advantage of prolonged
activity and greater bioavailability. The sublingual route possesses
both of these advantages with a rapid onset of action, prolonged
activity and greater bioavailability (Abdel-Aleem 2003; Andolina
2003; Danielsson 1999; Hofmeyr 2005; Khan 2003; Tang 2002;
Zieman 1997).
Misoprostol intake was associated with a significant increase in
prostaglandin-mediated side effects including maternal pyrexia (at
least 38°C or at least 40°C), vomiting and shivering. Side effects
appear to be dose dependent. Maternal pyrexia, in particular, is
very rarewhen low-dosemisoprostol is used for inductionof labour
or termination of pregnancy (Alfirevic 2006; Dodd 2010). These
side effects appear to be associated with high doses of misoprostol
andmay impact themanagement of patientswithmajor obstetrical
haemorrhage. For instance, blood transfusion forms an essential
part of fluid resuscitation in women with major PPH, and a rise in
body temperature following misoprostol use could be incorrectly
labelled as a “transfusion reaction”, with subsequent stoppage of
transfusion having a major impact on the general condition of the
patient. Similarly, maternal pyrexia could mistakenly be labelled
as “maternal sepsis”, which may result in the commencement of
unnecessary intravenous antibiotic therapy.
Three cases of deep vein thrombosis were reported in the
Ducloy-Bouthors 2011 study: two in the tranexamic acid group
and one in the control group (RR 2.00, 95% CI 0.19 to 21.57).
It is difficult to draw any conclusion regarding safety and risk of
thromboembolic complications after tranexamic acid administra-
tion. It is noteworthy that several large studies did not observe any
significant increase in the risk of thromboembolism (CRASH-2
trial collaborators 2010; Peitsidis 2011).
In this current update, we have not included postrandomisa-
tion haemoglobin level or disseminated intravascular coagulopa-
thy (DIC) as an outcome of interest for several reasons. First, blood
and clotting factor transfusions form an essential part of any pri-
mary PPH resuscitation protocol in women with massive obstetri-
cal haemorrhage. Therefore, a corrected haemoglobin level and/or
clotting factors may simply confirm adequate resuscitation, rather
than effectiveness of the uterotonics or the intervention. Second,
postdelivery haemoglobin level is directly related to pre-delivery
levels rather than the impact of intervention on blood loss. Ideally,
one should measure the drop in haemoglobin and/or hematocrit
levels before delivery and the first blood transfusion. However, as
primary PPH occurs unexpectedly, often among low-risk women,
pre-delivery haemoglobin and/or hematocrit levels usually are not
available. The trials by Winikoff 2010, Blum 2010 and Zuberi
2008 have set an example by checking haemoglobin concentration
for all labouring women before birth and after administration of
the trial drug. However, this will be very difficult to replicate in
other large pragmatic trials. Currently, lack of agreement has been
noted between clinicians regarding the definition of DIC (Gando
2006).
Two excluded quasi-randomised trials from the same centre
(Soltan 2009; Soltan 2010) evaluated the use of external aortic
compression devices in addition to conventional therapy in the
treatment of primary PPH. Investigators observed less blood trans-
fusion when this device was used (RR 0.55, 95% CI 0.45 to 0.66),
but the studies were too small to show an impact on other substan-
tive outcomes. Although the use of external aortic compression
devices was associated with abdominal discomfort and numbness
and a tingling sensation, the lack of any short- or long-term Is-
chaemic manifestations was quite reassuring. Currently, interest
in evaluating the non-pneumatic antishock garment (NASG) is
growing, especially in low-resource areas. With brief training, it
appears that individualswithout amedical background can use this
first-aid device. Miller and colleagues examined the use of NASG
in a pre-intervention/intervention study involving 1442 partici-
pants with hypovolaemic shock secondary to obstetrical haemor-
rhage from any cause and an estimated blood loss of at least 750
mL (Miller 2010). The NASG intervention was associated with a
significant reduction in measured blood loss, maternal mortality,
severe morbidities and emergency hysterectomy.
The question related to the management of women with major
primary PPH who remain unresponsive to medical management
with uterotonics and/or tranexamic acid therapy remains largely
unanswered. In the absence of randomised controlled trials, clin-
icians are left to make their own judgement on the best combina-
tion of surgical, radiological and/or pharmaceutical interventions
to control bleeding. Large double-blind,multi-centre, randomised
controlled trials are needed to evaluate the effects of surgical in-
terventions and/or radiological interventions on the primary out-
come measures; however, the inability to obtain informed consent
from critically ill patients may make it difficult to recruit partici-
pants. Clinicians should be encouraged to conduct such trials pro-
vided that they are able to follow agreed procedures for getting
consent from critically ill patients and to ensure that recruitment
does not interfere with standard clinical management.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Primary PPH is a life-threatening condition and availability of
first-aid treatment (IV line, parenteral fluids and uterotonics)
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is crucial. Current evidence suggests that intravenous oxytocin
should be used as first-line therapy for the treatment of primary
PPH due to uterine atony. Evidence suggests that misoprostol is
less effective than oxytocin and provides no additional uterotonic
effect when used simultaneously with conventional oxytocin treat-
ment. Efforts should be made to make injectable oxytocin avail-
able for use at deliveries occurring outside of facilities. When in-
jectable oxytocin is not available, misoprostol can be used.
Variation in dose regimens between the seven different misopros-
tol studies made it difficult for the review authors to draw clear
conclusions regarding the most effective dose or route. As first-
line treatment, the largest body of evidence available supports the
safety and effectiveness of an 800-mcg sublingual dose. As an ad-
junct treatment to standard oxytocin infusion, various routes were
examined, but none proved to be beneficial, so no regimen is sug-
gested at this time. In general, the use of higher doses should be
balanced against the likelihood of a greater incidence of maternal
side effects associated with misoprostol. A system of “adverse event
registration” might be helpful in identifying and tracking serious
maternal morbidity and mortality associated with the use of all
uterotonics in clinical practice.
Use of tranexamic acid in routine clinical practice is under in-
vestigation. The results of one ongoing trial, the WOMAN trial,
should be large enough to provide information on the effective-
ness and safety of this drug for women with primary PPH (Shakur
2010).
Lower segment compression is a simple and promising method,
particularly when unwell patients with major haemorrhage are
transferred between centres in low-resource settings, where access
to blood services is limited. Results from field studies of these
methods will be included in a future review.
We are unable to provide any guidance regarding the management
of women with primary PPH who fail to respond to uterotonics
and/or haemostatic drug therapies. However, it is logical to con-
sider conservative surgical techniques and/or radiological inter-
ventions in an effort to avoid hysterectomy. The main challenge is
to ensure that adequate clinical expertise is available at all times to
determine when the conservative approach should be abandoned
in favour of hysterectomy in a timely fashion.
Implications for research
High-quality studies with adequate power are urgently needed to
address our primary outcome measures. Future interventions ad-
dressing management of PPH at the community level would also
be useful. Studies seeking to identify appropriate uterotonic man-
agement of primary PPH following home deliveries, particularly
in developing countries, are of particular interest.
Currently, no randomised data are available on the effectiveness
of carbetocin, a long-acting synthetic oxytocin analogue, but re-
cent reports suggest that it may be of benefit in the prevention of
primary PPH (Su 2012) and, therefore, further research would be
justified.
Three areas of research would be of particular interest for women
with primary PPHunresponsive to uterotonics. First, further work
is needed to identify themost effective tamponade procedures and
uterine haemostatic suturing techniques in women with major
primary PPH. Second, aortic compression devices and the non-
pneumatic antishock garment should be tested further in patients
with major obstetrical haemorrhage. Finally, the benefits of inter-
ventional radiology for women at increased risk of bleeding during
delivery and for those who bleed following childbirth should be
critically evaluated in randomised trials. Ideally, first-line utero-
tonics and second-line surgical intervention trials should be con-
ducted in both developed and developing countries.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blum 2010
Methods Computer-generated random allocation sequence in blocks of 10. Sealed and numbered
opaque boxes contained the treatment allocation and were opened in strict numerical
sequence Participants received simultaneously either 40 IU oxytocin in a litre of intra-
venous solution over 15 minutes or 800 mcg (4 tablets of 200 mcg) misoprostol placed
under the tongue for 20 minutes and a placebo for the other treatment (i.e. 4 placebo
pills or an ampoule of saline)
Participants 809 women diagnosed with PPH due to uterine atony were randomly assigned to receive
800 mcg misoprostol or 40 IU intravenous oxytocin. Diagnosis of PPH was based on
need for treatment, as determined by clinical judgement or measured blood loss of 700
mL in the first hour after delivery, whichever occurred first
Women were excluded if their PPH was suspected to have a cause other than uterine
atony, if oxytocin was not received during the third stage of labour or if delivery was by
caesarean section
Interventions Prophylactic oxytocin given during the third stage of labour plus 800 mcg misoprostol
sublingually or 40 IU intravenous oxytocin after diagnosis of PPH due to uterine atony
Outcomes Primary outcome: cessation of active bleeding within 20 minutes and additional blood
loss of 300 mL or more after treatment
Secondary outcomes: total blood loss after treatment, change in haemoglobin after treat-
ment, time to active bleeding cessation, provision of any additional interventions and
side effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random allocation
sequence in blocks of 10
Allocation concealment (selection bias) Low risk Allocation sequence was not revealed un-
til data collection and cleaning were com-
pleted. Periodic monitoring to ensure hos-
pitals were following the numerical se-
quence of the boxes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants received simultaneously either
40 IU oxytocin in a litre of intravenous
solution over 15 minutes or 800 mcg (4
tablets of 200 mcg) misoprostol placed un-
der the tongue for 20minutes and a placebo
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Blum 2010 (Continued)
for the other treatment (i.e. 4 placebo pills
or an ampoule of saline). Periodic moni-
toring of hospitals to ensure masking was
successful
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% outcome data.
Selective reporting (reporting bias) Low risk Prior registration of protocol.
Other bias Unclear risk Outcome measure of additional blood loss
of 300 mL or more after treatment may
have included blood from episiotomy and
other liquids collected during delivery
Chantrapitak 2009
Methods Randomly assigned.
Participants Women, 28 to 42 weeks’ gestational age pregnancy, with vaginal delivery with PPH
defined as blood loss > 500mL (assessed byweighing soaking drapes and blood in bucket)
Interventions Conventional treatment plus lower uterine compression (either compression of lower
segment only or compression of lower segment with counteracting pressure from fundus)
for 10 minutes versus conventional treatment alone for PPH. Conventional treatment
is described as uterine massage, oxytocin (10 to 20 units in 1000 mL of intravenous
solution, 200 mL/min), intravenous ergometrine), placing cold pack on the uterus and
urinary catheterisation
Outcomes Main outcome: amount of blood loss in conventionally treated group versus experimental
group 2 hours after treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors indicated random generation using opaque concealed
envelopes
Allocation concealment (selection bias) High risk Clinicians were aware of intervention used.
Blinding (performance bias and detection
bias)
All outcomes
High risk Both participants and clinicians were aware of intervention used
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Chantrapitak 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data collected on all 64 randomly assigned women.
Selective reporting (reporting bias) Unclear risk No prior publication of protocol or statistical analysis plan
against which to assess
Other bias Unclear risk Outcome measure of blood loss may have included blood and
other liquids collected during delivery
Ducloy-Bouthors 2011
Methods Randomised, open-label, multi-centre trial. Randomisation sequence was generated by
a central computer, and randomisation was balanced by centre
Participants Women with measured blood loss > 800 mL following vaginal delivery were included
in the study. All participants with PPH > 500 mL were managed according to French
practice guidelines: bladder catheter, manual removal of retained placenta, genital tract
examination, uterine exploration and oxytocin (30 U/30 min), followed, and if these
procedures were inefficacious, sulprostone was administered (500 µg in 1 hour) with no
procoagulant treatment. Participants with PPH > 800 mL were included in the study.
Immediately after inclusion, participants were randomly assigned to receive tranexamic
acid (tranexamic acid group) or no antifibrinolytic treatment (control group)
Exclusion criteria were age < 18 years, absence of informed consent, caesarean section,
presence of knownhaemostatic abnormalities before pregnancy andhistory of thrombosis
or epilepsy
All women were managed according to French practice guidelines: bladder catheter,
manual removal of retained placenta, genital tract examination, uterine exploration and
oxytocin (30 U/30 min), followed, and if these procedures were inefficacious, sulpros-
tone (an analogue of prostaglandin E2 was administered 500 mcg in 1 hour) with no
procoagulant treatment
Interventions Tranexamic acid of loading dose 4 grams intravenously over 1 hour, then infusion of 1
g/h over 6 hours versus no antifibrinolytics
Outcomes Primary outcome was volume of blood loss between T1 and T4 (T1 = inclusion and T4
= T1 + 6 hours)
Secondary outcomes were:
• duration of bleeding; and
• impact of tranexamic acid on PPH-related outcome:
◦ Decrease in haemoglobin concentration
◦ Transfusion of packed red blood cells at T4 and at day 42
◦ Need for invasive procedures (uterine artery embolisation or ligature,
hysterectomy)
◦ Late postpartum curettage
◦ General outcome (intensive care unit stay, use of vasopressors, dyspnoea,
renal and multiple organ failure)
◦ Severe PPH, defined according to Charbit et al as exhibiting 1 of the
following criteria: peripartum decrease of haemoglobin > 4 g/dL, with the last
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Ducloy-Bouthors 2011 (Continued)
haemoglobin value before delivery considered as the reference, transfusion of at least 4
packed red blood cells, invasive haemostatic intervention, death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence was generated by
a central computer, and randomisation was
balanced by centre
Allocation concealment (selection bias) Unclear risk Allocation is described as being concealed
to outcome assessors. Obstetricians, mid-
wives andparticipantswere not aware of the
intervention used. However, anaesthetists
were aware of the intervention and were re-
sponsible for randomisation and adminis-
tration of the trial drug. It is unclear how
the allocated interventionwas concealed, as
the intravenous infusion would be visible
to all
Blinding (performance bias and detection
bias)
All outcomes
High risk Open labelled.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 152 women randomly assigned, and data
on 151 women reported in intention-to-
treat analysis
Selective reporting (reporting bias) High risk Public registration of protocol done nearly
3 years after study completion. Report pub-
lished several years after end of trial
Other bias Unclear risk Outcome measure of blood loss may have
included blood and other liquids collected
during delivery
Hofmeyr 2004
Methods Next in a series of treatment packs containing 5 tablets of independently prepared,
ordered in computer-generated random sequence and numbered consecutively. Packs
contained either placebo or misoprostol 5 × 200 mcg
Participants 244 women with bleeding more than expected at least 10 minutes after delivery thought
to be due to uterine atony and requiring additional uterotonic therapy
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Hofmeyr 2004 (Continued)
Interventions Routine active management of the third stage of labour with oxytocin 10 units or syn-
tometrine 1 ampoule soon after birth. All participants were given all routine treatments
for PPH (intravenous infusion, uterotonics, etc) from a special ’PPHTrolly’. Trial tablets
(misoprostol 200 mcg or placebo) were administered: 1 orally, 2 sublingually and 2 rec-
tally
Outcomes Primary outcomes:
• Measured blood loss 500 mL or more in first hour after enrolment
• Mean measured blood loss in first hour after enrolment
• Haemoglobin level day 1 after birth < 6 g/dL or blood transfusion
• Side effects (pyrexia 38.5 degrees Celsius or more, moderate or severe shivering 1
hour after enrolment)
Secondary outcomes:
• Blood loss 1000 mL or more in first hour after enrolment
• Blood transfusion
• Haemoglobin level first day after birth < 8 g/dL or blood transfusion
• Additional uterotonic given after enrolment
• Manual removal of the placenta
• Evacuation of retained products of conception
• Hysterectomy
• Maternal death
Notes 6/244 data sheets did not have pack numbers completed and were excluded from the
analysis. No abnormal outcomes were observed in any of the excluded group except 1
case of shivering and 1 of blood transfusion. No information given regarding allocation
group. Authors were contacted to clarify amount of blood loss before recruitment, and
they have provided the following information
• The trial was planned as a PPH treatment trial to assess the effect of misoprostol
over and above routine treatment of PPH.
• Entry criteria were intended to identify women who had PPH requiring
additional treatment. No blood loss criterion was included, as clinically we diagnose
PPH on the basis of ongoing abnormal bleeding, irrespective of the volume lost so far.
Thus, all participants, in the opinion of the attending clinician, had abnormal bleeding
requiring treatment. It is likely that, in most cases, this would have been more than 500
mL, but we do not have these data.
• 10 minutes was the minimum time after delivery, but in most cases, the time was
longer (in the 3 cases of maternal mortality, enrolment ranged between 85 and 140
minutes after delivery).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk .Computer-generated random sequence
and numbered consecutively
Allocation concealment (selection bias) Low risk Adequate, as participants were allocated as
next in a series of treatment packs contain-
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Hofmeyr 2004 (Continued)
ing 5 tablets of independently prepared trial
drug (misoprostol or placebo)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Treatment sequence was kept sealed, and
the code was broken only after complete
entry and checking of all trial data
Incomplete outcome data (attrition bias)
All outcomes
Low risk 244 women were randomly assigned. Pack
numbers for 6 women were incompletely
filled in on the data sheets. Group allo-
cation of these women was therefore un-
known, and they could not be included in
the analysis
Selective reporting (reporting bias) Unclear risk No prior public registration of protocol.
Other bias Unclear risk Outcome measure of blood loss may have
included blood and other liquids collected
during delivery
Lokugamage 2001
Methods Random allocation by sealed sequentially numbered envelopes. No blinding
Participants 64 women with primary PPH > 500 mL in 2 centres. Women with hypertension at
recruitment, cardiac abnormalities, ongoing severe asthma, connective tissue disorders,
haemorrhage due to obvious genital tract trauma. Any contraindications to prostaglandin
therapy were excluded
Interventions Syntometrine + syntocinon intravenous infusion + 4 placebo tablets per rectum versus
800mcg (4 tablets)misoprostol per rectum+ a placebo normal saline 2mL intramuscular
injection + placebo crystalloid intravenous infusion
Outcomes Effectiveness to control PPH within 20 minutes of administration
Notes Single-blinded study, as obstetricians were aware of the type of drug given, and women
and midwives were blinded
No mention of (a) drugs used in the third stage; (b) measurement of blood loss
Outcome measures for the following factors were reported as P value only:
(a) DIC; (b) blood transfusion; (c) length of hospital stay; (d) drug side effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by generat-
ing random numbers via STATA, a statis-
tical software package
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Lokugamage 2001 (Continued)
Allocation concealment (selection bias) Low risk Sealed, sequentially numbered opaque en-
velopes were used, and they were opened
in succession once a participant had been
recruited
Blinding (performance bias and detection
bias)
All outcomes
High risk Midwives were blinded to treatment, al-
though obstetricians and research doctor
were aware of the randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 64 participants are presented in the final
results, 32 participants having been allo-
cated to each armof the study. 1 participant
was recruited to the misoprostol arm but
was excluded from the analysis because the
haemorrhage was due to uterine rupture
Selective reporting (reporting bias) High risk Certain outcome data were reported as “P”
value of significance. Therefore, data can-
not be entered in a meta-analysis
No attempt was made to measure blood
loss, and it was not reported as an outcome
measure
No prior public registration of protocol.
Other bias High risk Original sample size calculation: 142 par-
ticipants needed to be recruited. How-
ever, the first year interim analysis, which
included 15 participants per study arm,
showed that misoprostol performed best.
The decision was made to terminate the
study after recruitment of 64 participants,
as the difference between the 2 treat-
ment regimens reached statistical signifi-
cance with power in excess of 80%
As the study is a single-blinded study, the
interim results may have influenced clini-
cians’ management
Walraven 2004
Methods Next in a series of randomised treatment packs in opaque envelopes with 3 tablets of
misoprostol 200 mcg or placebo
Participants 160 women who delivered vaginally with measured postpartum blood loss of 500 mL
or more within 1 hour of delivery and inadequate uterine contraction thought to be the
possible factor. Exclusion criteria included women who delivered by caesarean section
if blood loss was less than 500 mL in first hour following vaginal delivery, if gestational
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age was less than 28 weeks or if inadequate uterine contraction was not thought to be
the causative factor for PPH
Interventions Routine active management of third stage of labour with oxytocin 10 IU or syntometrine
1 ampoule (5 mL). All participants had standard management of PPH (rubbing the
uterus, commencing intravenous infusion, administering oxytocics, delivering the pla-
centa if undelivered and emptying the bladder)
Trial tablets (misoprostol 200 mcg or placebo) were administered: 1 orally and 2 sublin-
gually
Outcomes Primary outcome: additional blood loss after enrolment.
Secondary outcomes: frequency and severity of side effects, additional blood loss of 500
mL or more after enrolment, clinical complications (blood transfusion, hysterectomy)
and haemoglobin level at 12 to 24 hours after delivery
Notes Blinding may have been compromised by non-identical placebos
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Next in a series of randomised treatment
packs in opaque envelopes containing
misoprostol 3 200 Ag or placebo tablets.
Allocation concealment (selection bias) Low risk The randomisation code was broken only
after entry and checking of data. An in-
dependent data monitor reviewed the data
collected from the first 80 women and rec-
ommended that the study continue until
complete recruitment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Although this is a double-blind trial, the au-
thors indicated that the tablets were similar
in size and colour but not in shape. Efforts
to obtain identical placebo tablets were un-
successful. Although no account indicated
that the midwife caught sight of the tablet,
this is not a sufficient guarantee of adequate
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals after enrolment were re-
ported, and all outcomes were analysed ac-
cording to the allocated study group
Selective reporting (reporting bias) Unclear risk No prior publication of protocol.
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Other bias Unclear risk Outcome measure of blood loss may have
included blood and other liquids collected
during delivery
Widmer 2010
Methods A computer-generated randomisation sequence derived centrally in United States and
stratified by country. Within the strata, women were individually allocated by block
randomisation (varying blocks of 6 and 8)
Participants 1422womenwith clinically diagnosed PPH that was suspected to be due to uterine atony,
and they needed additional uterotonics. Participants were enrolled from hospitals in
Argentina, Egypt, South Africa, Thailand and Vietnam.Women were not eligible for the
trial if delivery was by caesarean section; misoprostol could not be given sublingually; any
severe allergic or bleeding disorders (e.g. haemophilia) were recorded; temperature was
higher than 38·5°C; delivery was defined as a miscarriage according to local gestational
age limits; or the placenta was not delivered
Interventions 600 µg misoprostol sublingually (3 tablets of 200 µg) or matching placebo in addition
to standard care for PPH according to local protocol
Outcomes Primary outcome: blood loss ≥ 500 mL within 60 minutes after randomisation
Secondary outcomes: need for blood transfusion; haemoglobin concentration of less than
80 g/L within 24 hours postpartum or need for blood transfusion; median blood loss at
60minutes and 90 minutes after randomisation; blood loss of 500 mL or more within 90
minutes after randomisation; blood loss of 1000 mL or more within 60 minutes and 90
minutes after randomisation; need for any additional uterotonic; maternal death; severe
morbidity (hysterectomy or admission to a maternal intensive care unit); side effects
(shivering, pyrexia, diarrhoea, vomiting or nausea) within 60 minutes and 90 minutes
after randomisation; and need for any other interventions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence derived centrally and stratified by
country. Within the strata, women were
individually allocated by block randomisa-
tion (varying blocks of 6 and 8)
Allocation concealment (selection bias) Low risk Randomisation code was not shown to any
participating trial centre or member of the
study team until the trial was closed. To
conceal allocation, treatment boxes were
sealed and numbered sequentially accord-
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Widmer 2010 (Continued)
ing to the randomisation sequence and
were distributed in the order that women
were judged to be eligible andwere enrolled
in the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Treatment boxes were identical in appear-
ance for both groups, and placebo tablets
were identical to misoprostol tablets in
shape, colour, weight, feel and taste
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomly assigned participants in-
cluded in analysis.
Selective reporting (reporting bias) Unclear risk No prior public registration of protocol.
Other bias Unclear risk Outcome measure of blood loss may have
included blood and other liquids collected
during delivery
Winikoff 2010
Methods Computer-generated random allocation sequence in blocks of 10 and concealed from
study staff who enrolled andwere allocated. Sealed and opaque packets were administered
to participants in the order that they were diagnosed, and providers and women were
masked to treatment assignment
Participants 978 women with PPH where administration of oxytocic drugs during the second (e.
g. induction or augmentation) and third stages of labour (active management) was not
routine practice. Diagnosis of PPH could occur at any time and at any amount of
blood loss; however, the protocol instructed providers to begin treatment immediately
if measured blood loss exceeded 700 mL
Women who had a known allergy to prostaglandin, had received any uterotonic drug in
labour or had a caesarean section or delivered outside the study site, or whose postpartum
bleeding was not suspected to be due to atonic uterus, were excluded from the study
Interventions Either 1 ampoule of 40 IU oxytocin or 4 tablets of 200 mcg misoprostol and matching
placebo (either 1 ampoule of saline solution or 4 placebo tablets resembling misoprostol)
, which were administered simultaneously. Oxytocin or saline solution was administered
in a litre of intravenous solution over 15 minutes, and misoprostol or placebo tablets
were placed under the tongue for 20 minutes
Outcomes Primary outcomes were the proportion of women who ceased active bleeding within 20
minutes after study treatment alone and those who lost 300 mL or more of blood after
treatment
Secondary outcomes were total blood loss after treatment, change in haemoglobin con-
centration after treatment, time to active bleeding cessation and any other additional
interventions. All outcomes were assessed from the time of initial treatment
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random allocation
sequence in blocks of 10
Allocation concealment (selection bias) Low risk Randomisation codes were maintained
centrally and were concealed from study
staff who enrolled and allocated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Sealed and opaque packets were adminis-
tered to participants in the order in which
they were diagnosed. Every packet con-
tained 1 active treatment (either 1 am-
poule of 40 IU oxytocin or 4 tablets of
200µgmisoprostol) andmatching placebo
(either 1 ampoule of saline solution or
4 placebo tablets resembling misoprostol)
. Note: Only visual matching of placebo
tablets to active. Matching of taste not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported on all randomly as-
signed participants.
Selective reporting (reporting bias) Low risk Prior registration of protocol.
Other bias Unclear risk Outcome measure of blood loss may have
included blood and other liquids collected
during delivery
Zhou 2006
Methods Randomised.
Participants 112 puerperants with PPH due to uterine atony who received routine management for
uterine atony. Exclusions were as follows: younger than 18 years of age; any pre-existing
heart condition; high blood pressure for which they had received medication in the
previous 2 years; any pre-existing blood condition, whether from birth or contracted
later in life, such as haemophilia; history of suffering from or exhibiting symptoms of
progressive hepatitis or endocrinosis; having undergone traditional caesarean; having
undergone general anaesthetic in case of placenta previa, or if the cervical muscles had
undergone surgery
52 assigned to test group, 60 to control group.
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Interventions 4 mg estradiol benzoate injected intramuscularly with routine management when bleed-
ing exceeded 500 mL versus routine management only for the control group. Routine
management of the control group was described as ’uterine massage and uterotonics
administration’ and included ’20 U cervical muscle injection to contract the uterus; 20
U intravenous drip to contract the uterus. In case of the cervical muscles not restoring,
injection or intravenous drip did not exceed 80 U. Where rate of blood loss exceeded
2000 ml, hysterectomy was performed’
Outcomes Rate of blood loss at 2 hours and 2 to 24 hours and any reported instances of hysterectomy
up to 24 hours
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Authors reported data only for blood loss and hysterectomy.
Selective reporting (reporting bias) High risk Authors reported data only for blood loss and hysterectomy.
No prior public registration of protocol.
Other bias High risk Unclear how blood loss was measured.
No sample size calculation. We were unable to identify manage-
ment before randomisation
Zuberi 2008
Methods Sample was randomly assigned in blocks of 10, stratified by site, using a computer-
generated random sequence. Eligible women were randomly assigned to next study
envelope. Each study envelope contained 3 tablets of misoprostol (200 mcg × 3) or
matching placebo
Participants 61 participants from a planned sample of 900 women with PPH (defined as measured
blood loss of 500 mL) had been reached. Women with cesarean section, gestational age
less than 28 weeks at time of delivery or not consenting were excluded from the study
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Interventions 600 mcg of misoprostol or matching placebo taken sublingually, in addition to standard
treatment for PPH
Standard treatment was management of the third stage of labour with standard utero-
tonics, controlled cord traction after delivery of baby and gentle uterine massage after
delivery of the placenta. At delivery of the anterior shoulder of the baby, 1 of 2 uterotonic
regimens was administered: intravenous 10 IU of oxytocin or 5 IU of oxytocin plus 0.4
mg of ergometrine given intramuscularly or intravenously
Outcomes Primary endpoint was measured blood loss ≥ 500 mL after PPH treatment
Secondary outcomes included change in haemoglobin, side effects, need for additional
interventions including blood transfusion, additional uterotonics, balloon tamponade
and hysterectomy and mean blood loss
Notes Only 61 participants of a planned sample of 900 recruited.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sample was randomly assigned in blocks
of 10, stratified by site, using a computer-
generated random sequence
Allocation concealment (selection bias) Low risk Randomisation code was concealed until
all data were entered and cleaned
Blinding (performance bias and detection
bias)
All outcomes
Low risk Use of the next randomised study envelope;
each contained 3 tablets of either miso-
prostol (200 mcg × 3) or matching placebo
(matching not described)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Main outcome data presented for 59 of the
61 randomly assigned participants
Selective reporting (reporting bias) Low risk Prior public registration of protocol.
Other bias High risk Failure to recruit sufficient participants to
meet sample size and power requirements
of the study
Bias in outcome measurement: Blood loss
was collected on used gauze pieces and pads
that were counted and placed in a plas-
tic bag. The plastic bag was then weighed;
however, accurate use of the scales proved
difficult; these results could not be verified
and were excluded
DIC: disseminated intravascular coagulopathies.
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EACD: external aortic compression device.
IU: international units.
min: minutes.
PPH: postpartum haemorrhage.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Deneux-Tharaux 2010 A multifaceted intervention aimed at increasing the translation into practice of a protocol for early man-
agement of PPH
Khalil 2011 The current study was carried out to evaluate the effectiveness of a new technique for keeping the Bakri
balloon in place among women with major primary PPH. All participants had a Bakri balloon inserted
with the same technique, but they were randomly assigned to (a) Bakri balloon and a stitch to keep it in
place or (b) Bakri balloon without a stitch. The current intervention of using “a stitch” was not direct for
the treatment of primary PPH
Khireddine 2012 This study was excluded, as it was a non-randomised population-base case-controlled study that examined
the association between induction of labour and postpartum haemorrhage, according to its indications and
methods, in low-risk parturient women
Magwali 2012 This study was a non-randomised study that compared blood loss and mortality in participants with severe
obstetrical haemorrhage who received standard care in phase 1 (0ctober 2007 to October 2008) versus
standard of care plus non-pneumatic antishock garment (NASG) in phase 2 (October 2008 to October
2009) at 2 referral hospitals in Harare
Soltan 2009 This study was excluded, as it was a quasi-randomisation trial. 300 participants, with blood loss of 500
mL from a non-contracted uterus associated with signs of circulatory compromise (e.g. tachycardia and/
or moderate to severe hypotension), were allocated in an alternative fashion to external aortic compression
devices (EACDs) as a first intervention line simultaneously with conventional management versus con-
ventional management alone. Main outcome measures were maternal mortality, surgical operation (e.g.
hysterectomy) and quantity of uterotonic drugs and blood transfusion units used. Time inminutes required
for cessation of uterine bleeding and side effects of EACD in relation to duration of use were recorded.
Period of follow-up was not defined. Authors presented data for only 240 women (120 participants in each
arm). Reasons for exclusion of 60 participants were unclear
Soltan 2010 This study was excluded, as it was a quasi-randomisation trial. 120 women with blood loss of 500 mL
from a non-contracted uterus associated with signs of circulatory compromise (e.g. tachycardia and/or
moderate to severe hypotension) were allocated in an alternative fashion EACD as a first intervention line
simultaneously with conventional management versus conventional management alone. Exclusion criteria
included women undergoing a caesarean delivery, known lower limb ischaemia, deep venous thrombosis
and peripheral neuritis or other neurological, respiratory, hepatic, renal or intestinal disorders. Aims of the
study were to monitor femoral artery blood flow by Doppler velocimetry in women treated for PPH with
and without the adjunct of the EACD and to assess possible adverse effects of the aortic compression device.
Authors did not provide enough information regarding obstetrical outcome measures
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Takagi 1976 The study consists of 2 parts. The first part was a retrospective analysis of data obtained before the clinical
trial. The clinical trial compared the effects of prostaglandin F2 alpha and ergot derivatives on the amount of
blood loss in women who suffered PPH as blood loss > 400 mL in primiparas and > 300 mL in multiparas.
13 women were randomly assigned to receive ergot derivatives, and 46 women received prostaglandin F2
alpha by 1 of the following routes: (1) gluteal intramuscular; (2) intravenous infusion; (3) transabdominal
intramyometrial; or (4) transvaginal intramyometrial. Method of randomisation was not reported.We were
unable to extract data according to allocated groups to perform an ’intention-to-treat’ analysis
PPH: postpartum haemorrhage
Characteristics of studies awaiting assessment [ordered by study ID]
Lavigne-Lissalde 2013
Methods Block randomisation according to site.
Participants Women with severe postpartum haemorrhage.
Interventions Standard care plus recombinant activated factor VII (rhuVIIa) versus standard care only
Outcomes Impact on use of second-line therapy.
Notes Not enough information in abstract for appraisal.
Characteristics of ongoing studies [ordered by study ID]
Collins 2013
Trial name or title Fibrinogen concentrate to treat postpartum haemorrhage - OBS2 Study
Methods A multicentre, prospective, double blind randomised control trial
Participants Women experiencing major postpartum haemorrhage (PPH). About 1050 women will be recruited into the
observational phase of the study so that 60 can be randomised to receive fibrinogen concentrate or placebo
Interventions Fibrinogen concentrate (RiaStap®) versus placebo.
The woman will receive a bolus infusion of either fibrinogen concentrate or placebo plus standard treatment
The dose of fibrinogen concentrate or placebo to be infused will be calculated based on the woman’s ideal
body weight for height and the measured FIBTEM A5 with the aim of increasing the FIBTEM A5 to 23 mm
Outcomes Primary endpoints: The total number of allogeneic blood products transfused after study medication until
discharge. The total number of allogeneic blood products transfused will be compared between the two arms
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Starting date May 2013
Contact information Dr P Collins, Reader in Haematology, Dept of Haematology, School of Medicine, Cardiff University, Heath
Park, Cardiff, CF14 4XN
Tel : 02920744144
E-mail :peter.collins@wales.nhs.uk
Notes Estimated end: September 2014
Miller 2008
Trial name or title Non-pneumatic anti-shock garment for obstetrical haemorrhage: Zambia and Zimbabwe (NASG)
Methods Cluster-randomised controlled trial.
Participants Approximately 2340 women who are pregnant or postpartum and experiencing obstetrical haemorrhage with
2 of the following 3: blood loss > 500 mL (at SHF, 1000 mL at RH) SBP < 100 mm Hg, pulse > 100 bpm
Interventions Half of the study clinics will use the non-pneumatic antishock garment on participants before transporting
them to the referral hospital for intervention
Outcomes Frequency of mortalities and frequency of severe morbidities combined as extreme adverse outcomes
Starting date October 2007.
Contact information suellenmiller@gmail.com
Notes Estimated end: May 2012.
Mirzazada 2011
Trial name or title Misoprostol for the treatment of postpartumhaemorrhage (PPH) following self-administration ofmisoprostol
prophylaxis in home deliveries
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women with clinical diagnosis of postpartum haemorrhage following home birth in 4 districts in Badakshan
Province in Afghanistan. All women enrolled in the study will receive 600 mcg misoprostol to be self-
administered as prophylaxis for PPH after delivery of the baby and before delivery of the placenta
Interventions Misoprostol 800 mcg administered sublingually versus placebo
Outcomes Proportion of women who experience a drop in haemoglobin concentration greater than 2 g/dL from before
delivery to after delivery. Outcomes will be compared between the 2 treatment arms
Starting date July 2012.
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Contact information dabbas@gynuity.org
Notes
Shakur 2010
Trial name or title Tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind
placebo controlled trial (the WOMAN trial)
Methods Randomised, double-blind, placebo-controlled trial.
Participants 15,000 women with clinician-diagnosed postpartum haemorrhage
Interventions Tranexamic acid versus placebo.
Outcomes Proportion of women who die or undergo hysterectomy. The primary cause of death will be described
Starting date May 2009.
Contact information thewomantrial@lshtm.ac.uk
Notes Estimated end: February 2015.
Wikkelsoe 2012
Trial name or title FIB-PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a
randomised controlled trial
Methods Randomised, double-blind, placebo-controlled trial.
Participants 245 women with 1 of the following: (1) following vaginal delivery with estimated blood loss exceeding 500
mL and intended manual removal of the placenta, (2) estimated blood loss exceeding 1000 mL and intended
manual exploration of the uterus due to continuous bleeding after the birth of the placenta, (3) following
caesarean section with estimated perioperative blood loss exceeding 1000 mL
Interventions Fibrinogen versus placebo.
Outcomes Need for blood transfusion.
Starting date June 2011.
Contact information wikkelsoe@gmail.com
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously
treated with conventional uterotonics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 4 1881 Risk Ratio (M-H, Fixed, 95% CI) 6.16 [0.75, 50.85]
1.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 5.08 [0.24, 105.73]
1.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 238 Risk Ratio (M-H, Fixed, 95% CI) 7.24 [0.38, 138.60]
2 Serious maternal morbidity 2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.31]
2.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.31]
2.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Admission to intensive care unit 2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.30, 2.11]
3.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.30, 2.11]
3.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Hysterectomy 4 1881 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.16, 5.41]
4.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.11, 4.05]
4.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.20]
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4.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 238 Risk Ratio (M-H, Random, 95% CI) 7.24 [0.38, 138.60]
5 Average blood loss after
enrolment in millilitres
4 1880 Mean Difference (IV, Fixed, 95% CI) -3.87 [-23.63, 15.
88]
5.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Mean Difference (IV, Fixed, 95% CI) 1.18 [-21.61, 23.98]
5.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Mean Difference (IV, Fixed, 95% CI) -85.0 [-189.23, 19.
23]
5.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 237 Mean Difference (IV, Fixed, 95% CI) -8.0 [-50.78, 34.78]
6 Blood loss 500 mL or more after
enrolment
4 1880 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.12]
6.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.78, 1.29]
6.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.32, 1.06]
6.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 237 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.21, 1.46]
7 Blood transfusion 4 1877 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.77, 1.17]
7.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.71, 1.14]
7.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.49, 2.14]
7.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 234 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.70, 2.45]
8 Blood loss 1000 mL or more
after enrolment
4 1880 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.42, 1.86]
8.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.41, 2.55]
8.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.08, 2.05]
8.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 237 Risk Ratio (M-H, Fixed, 95% CI) 3.08 [0.13, 74.76]
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9 Additional uterotonics 4 1866 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.84, 1.08]
9.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.82, 1.10]
9.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.15, 2.49]
9.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.27]
10 Manual removal of the placenta
after enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.44, 1.08]
10.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.44, 1.08]
10.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Uterine tamponade after
enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.07, 1.40]
11.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.07, 1.40]
11.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Artery ligation (uterine and/or
hypogastric arteries) after
enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.14, 7.20]
12.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.14, 7.20]
12.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Arterial embolisation after
enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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13.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14 Uterine compression stitch
after enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Evacuation of retained product
of conception
1 238 Risk Ratio (M-H, Fixed, 95% CI) 5.17 [0.25, 106.55]
15.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 238 Risk Ratio (M-H, Fixed, 95% CI) 5.17 [0.25, 106.55]
16 Any surgical co-interventions
(uterine tamponade, artery
ligations, arterial embolisation)
excluding hysterectomy after
enrolment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.15, 1.58]
16.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.15, 1.58]
16.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Nausea 3 1643 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.84, 1.67]
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17.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.87, 1.77]
17.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.15, 2.49]
17.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Vomiting 2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.16, 2.95]
18.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.16, 2.95]
18.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Diarrhoea 2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.37, 3.98]
19.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.37, 3.98]
19.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Maternal pyrexia 38 degrees or
more
4 1875 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [2.66, 3.67]
20.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 3.07 [2.61, 3.60]
20.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 9.23 [0.50, 168.57]
20.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 232 Risk Ratio (M-H, Fixed, 95% CI) 5.69 [1.29, 25.12]
21 Maternal pyrexia 40 degrees or
more
3 1715 Risk Ratio (M-H, Fixed, 95% CI) 13.58 [4.93, 37.44]
21.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 14.48 [4.91, 42.72]
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21.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 232 Risk Ratio (M-H, Fixed, 95% CI) 7.24 [0.38, 138.68]
22 Headache 3 1643 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.97, 1.53]
22.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.01, 1.62]
22.2 Misoprotol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.27, 1.60]
22.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Shivering 4 1877 Risk Ratio (M-H, Random, 95% CI) 2.25 [1.76, 2.88]
23.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
2 1483 Risk Ratio (M-H, Random, 95% CI) 3.47 [0.93, 13.01]
23.2 Misoprotol 200 mcg
oral/ 400 mcg sublingual versus
placebo no treatment
1 160 Risk Ratio (M-H, Random, 95% CI) 2.95 [1.40, 6.19]
23.3 Misoprotol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
1 234 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.50, 3.04]
24 Feeling faint or fainting 1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.66]
24.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.66]
24.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Allergy 1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
25.1 Misoprotol 600 mcg
sublingual versus placebo no
treatment
1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
25.2 Misoprostol 200 mcg
oral/400 mcg sublingual versus
placebo no treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
25.3 Misoprostol 200 mcg
oral/400 mcg sublingual/400
mcg rectal versus placebo no
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among
women who have not received any conventional uterotonic therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.06, 15.74]
1.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.06, 15.74]
2 Serious maternal morbidity 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
2.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
3 Admission to intensive care 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
3.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
4 Hysterectomy 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.36, 10.72]
4.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.36, 10.72]
5 Blood loss 500 mL or more after
enrolment
2 1787 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.69, 4.04]
5.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.69, 4.04]
6 Mean blood loss after enrolment 2 1787 Mean Difference (IV, Fixed, 95% CI) 44.86 [26.50, 63.22]
6.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Mean Difference (IV, Fixed, 95% CI) 44.86 [26.50, 63.22]
7 Blood loss 1000 mL or more
after enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [1.04, 6.75]
7.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [1.04, 6.75]
8 Blood transfusion within 24
hours
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.02, 2.14]
8.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.02, 2.14]
9 Duration from randomisation
till cessation of bleeding or
satisfactory response
2 1787 Mean Difference (IV, Fixed, 95% CI) 0.06 [-1.02, 1.14]
9.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Mean Difference (IV, Fixed, 95% CI) 0.06 [-1.02, 1.14]
10 Additional uterotonics after
enrolment
2 1787 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.57, 2.94]
10.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.57, 2.94]
11 Examination under anaesthesia 2 1787 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.87, 1.87]
11.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.87, 1.87]
12 Uterine tamponade after
enrolment
2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.07, 1.40]
12.1 600 mcg 2 1483 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.07, 1.40]
12.2 800 mcg 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Bimanual compression 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.96, 1.18]
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13.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.96, 1.18]
14 Artery ligation (uterine and/or
hypogastric arteries) after
enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Arterial embolisation after
enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Uterine tamponade after
enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Unsatisfactory response after
enrolment after enrolment
2 1787 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.02, 0.08]
17.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.02, 0.08]
18 Uterine compression stitch
after enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Any surgical co-interventions
(uterine tamponade, artery
ligations, arterial embolisation)
excluding hysterectomy after
enrolment
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
19.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
20 Nausea 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.25]
20.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.25]
21 Vomiting 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [1.45, 4.38]
21.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [1.45, 4.38]
22 Diarrhoea 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.44, 4.36]
22.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.44, 4.36]
23 Headache 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.23, 4.38]
23.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.23, 4.38]
24 Shivering 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [2.28, 3.19]
24.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [2.28, 3.19]
25 Feeling faint or fainting 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.73, 1.39]
25.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.73, 1.39]
26 Maternal pyrexia 38 degrees or
more
2 1787 Risk Difference (M-H, Random, 95% CI) 0.23 [-0.08, 0.54]
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26.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Difference (M-H, Random, 95% CI) 0.23 [-0.08, 0.54]
27 Maternal pyrexia 40 degrees or
more
2 1787 Risk Ratio (M-H, Random, 95% CI) 23.54 [0.50, 1104.
42]
27.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Random, 95% CI) 23.54 [0.50, 1104.
42]
28 Allergy 2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.09]
28.1 800 mcg misoprostol
versus 40 IU oxytocin
2 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.09]
Comparison 3. Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hysterectomy 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.89]
1.1 800 mcg 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.89]
2 Persistent haemorrhage 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.76]
3 Additional uterotonics 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.04, 0.76]
4 Surgical co-interventions
(excluding hysterectomy)
1 64 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.15, 6.67]
Comparison 4. Estrogen versus placebo/no treatment among women receiving conventional uterotonics for
primary PPH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hysterectomy 1 112 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 3.11]
2 Mean blood loss within two
hours
1 112 Mean Difference (IV, Fixed, 95% CI) -274.9 [-384.72, -
165.08]
3 Mean blood loss between two
and 24 hours
1 112 Mean Difference (IV, Fixed, 95% CI) -50.7 [-83.07, -18.
33]
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Comparison 5. Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics
for primary PPH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious maternal morbidity
(renal failure respiratory failure,
cardiac arrest, multiple organ
failure)
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.05]
3 Admission to intensive care unit 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.15, 2.42]
4 Hysterectomy 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.05]
5 Blood loss 500 mL or more after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.97, 1.03]
6 Blood loss 1000 mL or more
after enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.61, 2.09]
7 Total mean blood loss after
enrolment
1 144 Mean Difference (IV, Fixed, 95% CI) -91.0 [-242.00, 60.
00]
8 Blood transfusion within 24
hours
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.24, 1.40]
9 Additional uterotonics after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.76, 1.48]
10 Unsatisfactory response after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.03, 1.34]
11 Uterine compression stitch
after enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.09]
12 Interventions to control
bleeding for secondary
postpartum haemorrhage
1 288 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.93]
12.1 Medical interventions
to control bleeding (new
subgroup)
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.68]
12.2 Surgical evacuation 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.39]
13 Examination under anaesthesia 1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.97, 1.03]
14 Uterine tamponade after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Artery ligation (uterine and/or
hypogastric arteries) after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.05]
16 Arterial embolisation after
enrolment
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.22, 2.86]
17 Headache 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Nausea 1 144 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [1.46, 82.99]
19 Maternal pyrexia 38 degrees or
more
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.52, 2.31]
20 Maternal pyrexia 40 degrees or
more
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Deep vein thrombosis 1 144 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.57]
22 Seizures 1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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23 Dizziness 1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.31, 5.75]
24 Phosphenes 1 144 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.88, 18.19]
25 Secondary postpartum
haemorrhage
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.68]
26 Surgical evacuation for
secondary postpartum
haemorrhage
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.39]
27 Intravenous iron therapy in the
puerperium
1 108 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.89, 2.32]
28 Hospital re-admission
for secondary postpartum
haemorrhage
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.39]
29 Postnatal depression at day 42
postpartum
1 144 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.05]
Comparison 6. Lower uterine segment compression versus conventional treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious maternal morbidity 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Hysterectomy 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Blood loss 500 mL or more after
enrolment
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 0.94]
5 Blood loss 1000 mL or more
after enrolment
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 4.01]
6 Average blood loss after
enrolment
1 64 Mean Difference (IV, Fixed, 95% CI) -103.00 [-260.00,
52.00]
7 Blood transfusion 1 64 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.66, 8.23]
8 Other surgical interventions to
control bleeding (other than
hysterectomy)
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Unsatisfactory response after
enrolment
1 64 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.15, 6.67]
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Analysis 1.1. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 1 Maternal death.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 1 Maternal death
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 0/29 0/32 Not estimable
Widmer 2010 2/705 0/717 50.2 % 5.08 [ 0.24, 105.73 ]
Subtotal (95% CI) 734 749 50.2 % 5.08 [ 0.24, 105.73 ]
Total events: 2 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 0/79 0/81 Not estimable
Subtotal (95% CI) 79 81 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 3/117 0/121 49.8 % 7.24 [ 0.38, 138.60 ]
Subtotal (95% CI) 117 121 49.8 % 7.24 [ 0.38, 138.60 ]
Total events: 3 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 930 951 100.0 % 6.16 [ 0.75, 50.85 ]
Total events: 5 (Misoprostol), 0 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.2. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 2 Serious maternal morbidity.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 2 Serious maternal morbidity
Study or subgroup
Misoprostol
any route Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 0/705 1/717 100.0 % 0.34 [ 0.01, 8.31 ]
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 100.0 % 0.34 [ 0.01, 8.31 ]
Total events: 0 (Misoprostol any route), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol any route), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol any route), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.34 [ 0.01, 8.31 ]
Total events: 0 (Misoprostol any route), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 3 Admission to intensive care unit.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 3 Admission to intensive care unit
Study or subgroup
Sublingual
misorpros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 7/705 9/717 100.0 % 0.79 [ 0.30, 2.11 ]
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 100.0 % 0.79 [ 0.30, 2.11 ]
Total events: 7 (Sublingual misorprostol), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misorprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misorprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.79 [ 0.30, 2.11 ]
Total events: 7 (Sublingual misorprostol), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 4 Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 4 Hysterectomy
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 2/705 3/717 48.7 % 0.68 [ 0.11, 4.05 ]
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 48.7 % 0.68 [ 0.11, 4.05 ]
Total events: 2 (Misoprostol), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 0/79 2/81 25.2 % 0.21 [ 0.01, 4.20 ]
Subtotal (95% CI) 79 81 25.2 % 0.20 [ 0.01, 4.20 ]
Total events: 0 (Misoprostol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 3/117 0/121 26.1 % 7.24 [ 0.38, 138.60 ]
Subtotal (95% CI) 117 121 26.1 % 7.24 [ 0.38, 138.60 ]
Total events: 3 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 930 951 100.0 % 0.93 [ 0.16, 5.41 ]
Total events: 5 (Misoprostol), 5 (Placebo)
Heterogeneity: Tau2 = 0.83; Chi2 = 2.98, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 2.93, df = 2 (P = 0.23), I2 =32%
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Analysis 1.5. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 5 Average blood loss after enrolment
in millilitres.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 5 Average blood loss after enrolment in millilitres
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 705 250 (223) 717 248 (229) 70.7 % 2.00 [ -21.49, 25.49 ]
Zuberi 2008 29 175 (168) 32 187 (207) 4.4 % -12.00 [ -106.25, 82.25 ]
Subtotal (95% CI) 734 749 75.1 % 1.18 [ -21.61, 23.98 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 79 325 (264) 81 410 (397) 3.6 % -85.00 [ -189.23, 19.23 ]
Subtotal (95% CI) 79 81 3.6 % -85.00 [ -189.23, 19.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 117 168 (163) 120 176 (173) 21.3 % -8.00 [ -50.78, 34.78 ]
Subtotal (95% CI) 117 120 21.3 % -8.00 [ -50.78, 34.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 930 950 100.0 % -3.87 [ -23.63, 15.88 ]
Heterogeneity: Chi2 = 2.63, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 2.55, df = 2 (P = 0.28), I2 =22%
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Analysis 1.6. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 6 Blood loss 500 mL or more after
enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 6 Blood loss 500 mL or more after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 2/29 4/32 2.8 % 0.55 [ 0.11, 2.79 ]
Widmer 2010 100/705 100/717 72.6 % 1.02 [ 0.79, 1.31 ]
Subtotal (95% CI) 734 749 75.4 % 1.00 [ 0.78, 1.29 ]
Total events: 102 (Misoprostol), 104 (Placebo)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 13/79 23/81 16.6 % 0.58 [ 0.32, 1.06 ]
Subtotal (95% CI) 79 81 16.6 % 0.58 [ 0.32, 1.06 ]
Total events: 13 (Misoprostol), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 6/117 11/120 8.0 % 0.56 [ 0.21, 1.46 ]
Subtotal (95% CI) 117 120 8.0 % 0.56 [ 0.21, 1.46 ]
Total events: 6 (Misoprostol), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI) 930 950 100.0 % 0.89 [ 0.71, 1.12 ]
Total events: 121 (Misoprostol), 138 (Placebo)
Heterogeneity: Chi2 = 4.19, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 3.63, df = 2 (P = 0.16), I2 =45%
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Analysis 1.7. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 7 Blood transfusion.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 7 Blood transfusion
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 5/29 6/32 3.8 % 0.92 [ 0.31, 2.69 ]
Widmer 2010 103/705 117/717 78.2 % 0.90 [ 0.70, 1.14 ]
Subtotal (95% CI) 734 749 82.1 % 0.90 [ 0.71, 1.14 ]
Total events: 108 (Misoprostol), 123 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 12/79 12/81 8.0 % 1.03 [ 0.49, 2.14 ]
Subtotal (95% CI) 79 81 8.0 % 1.03 [ 0.49, 2.14 ]
Total events: 12 (Misoprostol), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 19/115 15/119 9.9 % 1.31 [ 0.70, 2.45 ]
Subtotal (95% CI) 115 119 9.9 % 1.31 [ 0.70, 2.45 ]
Total events: 19 (Misoprostol), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Total (95% CI) 928 949 100.0 % 0.95 [ 0.77, 1.17 ]
Total events: 139 (Misoprostol), 150 (Placebo)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 1.28, df = 2 (P = 0.53), I2 =0.0%
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Analysis 1.8. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 8 Blood loss 1000 mL or more after
enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 8 Blood loss 1000 mL or more after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 0/29 0/32 Not estimable
Widmer 2010 9/705 9/717 62.2 % 1.02 [ 0.41, 2.55 ]
Subtotal (95% CI) 734 749 62.2 % 1.02 [ 0.41, 2.55 ]
Total events: 9 (Misoprostol), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 2/79 5/81 34.4 % 0.41 [ 0.08, 2.05 ]
Subtotal (95% CI) 79 81 34.4 % 0.41 [ 0.08, 2.05 ]
Total events: 2 (Misoprostol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 1/117 0/120 3.4 % 3.08 [ 0.13, 74.76 ]
Subtotal (95% CI) 117 120 3.4 % 3.08 [ 0.13, 74.76 ]
Total events: 1 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 930 950 100.0 % 0.88 [ 0.42, 1.86 ]
Total events: 12 (Misoprostol), 14 (Placebo)
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Chi2 = 1.55, df = 2 (P = 0.46), I2 =0.0%
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Analysis 1.9. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 9 Additional uterotonics.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 9 Additional uterotonics
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 29/29 32/32 10.3 % 1.00 [ 0.94, 1.06 ]
Widmer 2010 188/705 203/717 67.1 % 0.94 [ 0.80, 1.12 ]
Subtotal (95% CI) 734 749 77.4 % 0.95 [ 0.82, 1.10 ]
Total events: 217 (Misoprostol), 235 (Placebo)
Heterogeneity: Chi2 = 2.60, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 3/79 5/81 1.6 % 0.62 [ 0.15, 2.49 ]
Subtotal (95% CI) 79 81 1.6 % 0.62 [ 0.15, 2.49 ]
Total events: 3 (Misoprostol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 63/111 63/112 20.9 % 1.01 [ 0.80, 1.27 ]
Subtotal (95% CI) 111 112 20.9 % 1.01 [ 0.80, 1.27 ]
Total events: 63 (Misoprostol), 63 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 924 942 100.0 % 0.96 [ 0.84, 1.08 ]
Total events: 283 (Misoprostol), 303 (Placebo)
Heterogeneity: Chi2 = 2.54, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.59, df = 2 (P = 0.75), I2 =0.0%
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Analysis 1.10. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 10 Manual removal of the placenta
after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 10 Manual removal of the placenta after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 29/705 42/717 92.5 % 0.70 [ 0.44, 1.11 ]
Zuberi 2008 2/29 4/32 7.5 % 0.55 [ 0.11, 2.79 ]
Subtotal (95% CI) 734 749 100.0 % 0.69 [ 0.44, 1.08 ]
Total events: 31 (Misoprostol), 46 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.69 [ 0.44, 1.08 ]
Total events: 31 (Misoprostol), 46 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 11 Uterine tamponade after
enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 11 Uterine tamponade after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 0/705 0/717 Not estimable
Zuberi 2008 2/29 7/32 100.0 % 0.32 [ 0.07, 1.40 ]
Subtotal (95% CI) 734 749 100.0 % 0.32 [ 0.07, 1.40 ]
Total events: 2 (Misoprostol), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.32 [ 0.07, 1.40 ]
Total events: 2 (Misoprostol), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 12 Artery ligation (uterine and/or
hypogastric arteries) after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 12 Artery ligation (uterine and/or hypogastric arteries) after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 2/705 2/717 100.0 % 1.02 [ 0.14, 7.20 ]
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 100.0 % 1.02 [ 0.14, 7.20 ]
Total events: 2 (Misoprostol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 1.02 [ 0.14, 7.20 ]
Total events: 2 (Misoprostol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 13 Arterial embolisation after
enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 13 Arterial embolisation after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 0/705 0/717 Not estimable
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.14. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 14 Uterine compression stitch after
enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 14 Uterine compression stitch after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 0/705 0/717 Not estimable
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.15. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 15 Evacuation of retained product of
conception.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 15 Evacuation of retained product of conception
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 2/117 0/121 100.0 % 5.17 [ 0.25, 106.55 ]
Subtotal (95% CI) 117 121 100.0 % 5.17 [ 0.25, 106.55 ]
Total events: 2 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 117 121 100.0 % 5.17 [ 0.25, 106.55 ]
Total events: 2 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 16 Any surgical co-interventions
(uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 16 Any surgical co-interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment
Study or subgroup Misoprostol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 2/705 2/717 36.7 % 1.02 [ 0.14, 7.20 ]
Zuberi 2008 2/29 7/32 63.3 % 0.32 [ 0.07, 1.40 ]
Subtotal (95% CI) 734 749 100.0 % 0.48 [ 0.15, 1.58 ]
Total events: 4 (Misoprostol), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.48 [ 0.15, 1.58 ]
Total events: 4 (Misoprostol), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 17 Nausea.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 17 Nausea
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 60/705 49/717 87.7 % 1.25 [ 0.87, 1.79 ]
Zuberi 2008 2/29 2/32 3.4 % 1.10 [ 0.17, 7.34 ]
Subtotal (95% CI) 734 749 91.1 % 1.24 [ 0.87, 1.77 ]
Total events: 62 (Sublingual misoprostol), 51 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 3/79 5/81 8.9 % 0.62 [ 0.15, 2.49 ]
Subtotal (95% CI) 79 81 8.9 % 0.62 [ 0.15, 2.49 ]
Total events: 3 (Sublingual misoprostol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 813 830 100.0 % 1.18 [ 0.84, 1.67 ]
Total events: 65 (Sublingual misoprostol), 56 (Placebo)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.18. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 18 Vomiting.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 18 Vomiting
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 45/705 25/717 96.3 % 1.83 [ 1.14, 2.95 ]
Zuberi 2008 2/29 1/32 3.7 % 2.21 [ 0.21, 23.08 ]
Subtotal (95% CI) 734 749 100.0 % 1.84 [ 1.16, 2.95 ]
Total events: 47 (Sublingual misoprostol), 26 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 1.84 [ 1.16, 2.95 ]
Total events: 47 (Sublingual misoprostol), 26 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 19 Diarrhoea.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 19 Diarrhoea
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 6/705 5/717 100.0 % 1.22 [ 0.37, 3.98 ]
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 734 749 100.0 % 1.22 [ 0.37, 3.98 ]
Total events: 6 (Sublingual misoprostol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 1.22 [ 0.37, 3.98 ]
Total events: 6 (Sublingual misoprostol), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 20 Maternal pyrexia 38 degrees or
more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 20 Maternal pyrexia 38 degrees or more
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 406/705 137/717 96.2 % 3.01 [ 2.56, 3.55 ]
Zuberi 2008 15/29 3/32 2.0 % 5.52 [ 1.78, 17.13 ]
Subtotal (95% CI) 734 749 98.3 % 3.07 [ 2.61, 3.60 ]
Total events: 421 (Sublingual misoprostol), 140 (Placebo)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 13.58 (P < 0.00001)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 4/79 0/81 0.3 % 9.23 [ 0.50, 168.57 ]
Subtotal (95% CI) 79 81 0.3 % 9.23 [ 0.50, 168.57 ]
Total events: 4 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 11/114 2/118 1.4 % 5.69 [ 1.29, 25.12 ]
Subtotal (95% CI) 114 118 1.4 % 5.69 [ 1.29, 25.12 ]
Total events: 11 (Sublingual misoprostol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.022)
Total (95% CI) 927 948 100.0 % 3.12 [ 2.66, 3.67 ]
Total events: 436 (Sublingual misoprostol), 142 (Placebo)
Heterogeneity: Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 13.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.20, df = 2 (P = 0.55), I2 =0.0%
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Analysis 1.21. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 21 Maternal pyrexia 40 degrees or
more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 21 Maternal pyrexia 40 degrees or more
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 48/705 3/717 75.5 % 16.27 [ 5.09, 52.00 ]
Zuberi 2008 1/29 0/32 12.1 % 3.30 [ 0.14, 77.95 ]
Subtotal (95% CI) 734 749 87.5 % 14.48 [ 4.91, 42.72 ]
Total events: 49 (Sublingual misoprostol), 3 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 4.84 (P < 0.00001)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 3/114 0/118 12.5 % 7.24 [ 0.38, 138.68 ]
Subtotal (95% CI) 114 118 12.5 % 7.24 [ 0.38, 138.68 ]
Total events: 3 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 848 867 100.0 % 13.58 [ 4.93, 37.44 ]
Total events: 52 (Sublingual misoprostol), 3 (Placebo)
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.22. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 22 Headache.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 22 Headache
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 125/705 101/717 89.8 % 1.26 [ 0.99, 1.60 ]
Zuberi 2008 2/29 0/32 0.4 % 5.50 [ 0.27, 110.01 ]
Subtotal (95% CI) 734 749 90.3 % 1.28 [ 1.01, 1.62 ]
Total events: 127 (Sublingual misoprostol), 101 (Placebo)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
2 Misoprotol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Walraven 2004 7/79 11/81 9.7 % 0.65 [ 0.27, 1.60 ]
Subtotal (95% CI) 79 81 9.7 % 0.65 [ 0.27, 1.60 ]
Total events: 7 (Sublingual misoprostol), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 813 830 100.0 % 1.22 [ 0.97, 1.53 ]
Total events: 134 (Sublingual misoprostol), 112 (Placebo)
Heterogeneity: Chi2 = 2.91, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Chi2 = 2.02, df = 1 (P = 0.15), I2 =51%
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Analysis 1.23. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 23 Shivering.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 23 Shivering
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Widmer 2010 514/705 252/717 59.3 % 2.07 [ 1.86, 2.31 ]
Zuberi 2008 15/29 2/32 3.0 % 8.28 [ 2.07, 33.13 ]
Subtotal (95% CI) 734 749 62.3 % 3.47 [ 0.93, 13.01 ]
Total events: 529 (Sublingual misoprostol), 254 (Placebo)
Heterogeneity: Tau2 = 0.72; Chi2 = 3.86, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.85 (P = 0.065)
2 Misoprotol 200 mcg oral/ 400 mcg sublingual versus placebo no treatment
Walraven 2004 23/79 8/81 9.4 % 2.95 [ 1.40, 6.19 ]
Subtotal (95% CI) 79 81 9.4 % 2.95 [ 1.40, 6.19 ]
Total events: 23 (Sublingual misoprostol), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0043)
3 Misoprotol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Hofmeyr 2004 63/116 30/118 28.3 % 2.14 [ 1.50, 3.04 ]
Subtotal (95% CI) 116 118 28.3 % 2.14 [ 1.50, 3.04 ]
Total events: 63 (Sublingual misoprostol), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.24 (P = 0.000023)
Total (95% CI) 929 948 100.0 % 2.25 [ 1.76, 2.88 ]
Total events: 615 (Sublingual misoprostol), 292 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.71, df = 3 (P = 0.19); I2 =36%
Test for overall effect: Z = 6.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.97, df = 2 (P = 0.62), I2 =0.0%
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Analysis 1.24. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 24 Feeling faint or fainting.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 24 Feeling faint or fainting
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 0/29 1/32 100.0 % 0.37 [ 0.02, 8.66 ]
Subtotal (95% CI) 29 32 100.0 % 0.37 [ 0.02, 8.66 ]
Total events: 0 (Sublingual misoprostol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 29 32 100.0 % 0.37 [ 0.02, 8.66 ]
Total events: 0 (Sublingual misoprostol), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Misoprostol (any route) versus placebo or no additional treatment given to
women simultaneously treated with conventional uterotonics, Outcome 25 Allergy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 1 Misoprostol (any route) versus placebo or no additional treatment given to women simultaneously treated with conventional uterotonics
Outcome: 25 Allergy
Study or subgroup
Sublingual
misopros-
tol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Misoprotol 600 mcg sublingual versus placebo no treatment
Zuberi 2008 0/29 0/32 Not estimable
Subtotal (95% CI) 29 32 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Misoprostol 200 mcg oral/400 mcg sublingual versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Misoprostol 200 mcg oral/400 mcg sublingual/400 mcg rectal versus placebo no treatment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 29 32 Not estimable
Total events: 0 (Sublingual misoprostol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.1. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 1 Maternal
mortality.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 1 Maternal mortality
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 1/407 1/402 100.0 % 0.99 [ 0.06, 15.74 ]
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 100.0 % 0.99 [ 0.06, 15.74 ]
Total events: 1 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 2 Serious
maternal morbidity.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 2 Serious maternal morbidity
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 1/402 100.0 % 0.33 [ 0.01, 8.06 ]
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 100.0 % 0.33 [ 0.01, 8.06 ]
Total events: 0 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 3 Admission
to intensive care.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 3 Admission to intensive care
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 1/402 100.0 % 0.33 [ 0.01, 8.06 ]
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 100.0 % 0.33 [ 0.01, 8.06 ]
Total events: 0 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 4
Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 4 Hysterectomy
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 4/407 2/402 100.0 % 1.98 [ 0.36, 10.72 ]
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 100.0 % 1.98 [ 0.36, 10.72 ]
Total events: 4 (sublingual misoprostol), 2 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 5 Blood loss
500 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 5 Blood loss 500 mL or more after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 58/407 53/402 52.1 % 1.08 [ 0.76, 1.53 ]
Winikoff 2010 53/488 20/490 47.9 % 2.66 [ 1.62, 4.38 ]
Total (95% CI) 895 892 100.0 % 1.66 [ 0.69, 4.04 ]
Total events: 111 (sublingual misoprostol), 73 (IV oxytocin)
Heterogeneity: Tau2 = 0.36; Chi2 = 8.54, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 6 Mean blood
loss after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 6 Mean blood loss after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 407 279 (251) 402 252 (205) 33.8 % 27.00 [ -4.56, 58.56 ]
Winikoff 2010 488 244 (186) 490 190 (174) 66.2 % 54.00 [ 31.42, 76.58 ]
Total (95% CI) 895 892 100.0 % 44.86 [ 26.50, 63.22 ]
Heterogeneity: Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 7 Blood loss
1000 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 7 Blood loss 1000 mL or more after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 11/407 3/402 50.2 % 3.62 [ 1.02, 12.88 ]
Winikoff 2010 5/488 3/490 49.8 % 1.67 [ 0.40, 6.96 ]
Total (95% CI) 895 892 100.0 % 2.65 [ 1.04, 6.75 ]
Total events: 16 (sublingual misoprostol), 6 (IV oxytocin)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 8 Blood
transfusion within 24 hours.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 8 Blood transfusion within 24 hours
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 24/407 18/402 41.1 % 1.32 [ 0.73, 2.39 ]
Winikoff 2010 41/488 26/490 58.9 % 1.58 [ 0.98, 2.55 ]
Total (95% CI) 895 892 100.0 % 1.47 [ 1.02, 2.14 ]
Total events: 65 (sublingual misoprostol), 44 (IV oxytocin)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 9 Duration
from randomisation till cessation of bleeding or satisfactory response.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 9 Duration from randomisation till cessation of bleeding or satisfactory response
Study or subgroup
sublingual
misopros-
tol IV oxytocin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 407 19.3 (15) 402 19.1 (14.6) 28.0 % 0.20 [ -1.84, 2.24 ]
Winikoff 2010 488 13.4 (8.2) 490 13.4 (11.8) 72.0 % 0.0 [ -1.27, 1.27 ]
Total (95% CI) 895 892 100.0 % 0.06 [ -1.02, 1.14 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 10 Additional
uterotonics after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 10 Additional uterotonics after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 40/407 46/402 50.2 % 0.86 [ 0.58, 1.28 ]
Winikoff 2010 61/488 31/490 49.8 % 1.98 [ 1.31, 2.99 ]
Total (95% CI) 895 892 100.0 % 1.30 [ 0.57, 2.94 ]
Total events: 101 (sublingual misoprostol), 77 (IV oxytocin)
Heterogeneity: Tau2 = 0.30; Chi2 = 8.05, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 11
Examination under anaesthesia.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 11 Examination under anaesthesia
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 37/407 22/402 35.0 % 1.66 [ 1.00, 2.76 ]
Winikoff 2010 99/488 90/490 65.0 % 1.10 [ 0.85, 1.43 ]
Total (95% CI) 895 892 100.0 % 1.27 [ 0.87, 1.87 ]
Total events: 136 (sublingual misoprostol), 112 (IV oxytocin)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.98, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours misoprostol Favours oxytocin
90Treatment for primary postpartum haemorrhage (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.12. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 12 Uterine
tamponade after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 12 Uterine tamponade after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 600 mcg
Widmer 2010 0/705 0/717 Not estimable
Zuberi 2008 2/29 7/32 100.0 % 0.32 [ 0.07, 1.40 ]
Subtotal (95% CI) 734 749 100.0 % 0.32 [ 0.07, 1.40 ]
Total events: 2 (sublingual misoprostol), 7 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 800 mcg
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (sublingual misoprostol), 0 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 734 749 100.0 % 0.32 [ 0.07, 1.40 ]
Total events: 2 (sublingual misoprostol), 7 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 13 Bimanual
compression.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 13 Bimanual compression
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 39/407 31/402 9.9 % 1.24 [ 0.79, 1.95 ]
Winikoff 2010 294/488 283/490 90.1 % 1.04 [ 0.94, 1.16 ]
Total (95% CI) 895 892 100.0 % 1.06 [ 0.96, 1.18 ]
Total events: 333 (sublingual misoprostol), 314 (IV oxytocin)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours misoprostol Favours oxytocin
92Treatment for primary postpartum haemorrhage (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.14. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 14 Artery
ligation (uterine and/or hypogastric arteries) after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 14 Artery ligation (uterine and/or hypogastric arteries) after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 0/402 Not estimable
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 Not estimable
Total events: 0 (sublingual misoprostol), 0 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.15. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 15 Arterial
embolisation after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 15 Arterial embolisation after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 0/402 Not estimable
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 Not estimable
Total events: 0 (sublingual misoprostol), 0 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.16. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 16 Uterine
tamponade after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 16 Uterine tamponade after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 0/402 Not estimable
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 Not estimable
Total events: 0 (sublingual misoprostol), 0 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.17. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 17
Unsatisfactory response after enrolment after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 17 Unsatisfactory response after enrolment after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 44/407 42/402 46.1 % 0.00 [ -0.04, 0.05 ]
Winikoff 2010 48/488 22/490 53.9 % 0.05 [ 0.02, 0.09 ]
Total (95% CI) 895 892 100.0 % 0.03 [ -0.02, 0.08 ]
Total events: 92 (sublingual misoprostol), 64 (IV oxytocin)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 18 Uterine
compression stitch after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 18 Uterine compression stitch after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 0/402 Not estimable
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 Not estimable
Total events: 0 (sublingual misoprostol), 0 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 2.19. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 19 Any
surgical co-interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy
after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 19 Any surgical co-interventions (uterine tamponade, artery ligations, arterial embolisation) excluding hysterectomy after enrolment
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 1/402 100.0 % 0.33 [ 0.01, 8.06 ]
Winikoff 2010 0/488 0/490 Not estimable
Total (95% CI) 895 892 100.0 % 0.33 [ 0.01, 8.06 ]
Total events: 0 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 20 Nausea.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 20 Nausea
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 59/407 69/402 62.9 % 0.84 [ 0.61, 1.16 ]
Winikoff 2010 49/488 41/490 37.1 % 1.20 [ 0.81, 1.78 ]
Total (95% CI) 895 892 100.0 % 0.98 [ 0.76, 1.25 ]
Total events: 108 (sublingual misoprostol), 110 (IV oxytocin)
Heterogeneity: Chi2 = 1.84, df = 1 (P = 0.18); I2 =46%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 21 Vomiting.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 21 Vomiting
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 19/407 10/402 59.0 % 1.88 [ 0.88, 3.99 ]
Winikoff 2010 24/488 7/490 41.0 % 3.44 [ 1.50, 7.92 ]
Total (95% CI) 895 892 100.0 % 2.52 [ 1.45, 4.38 ]
Total events: 43 (sublingual misoprostol), 17 (IV oxytocin)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 3.27 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 22 Diarrhoea.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 22 Diarrhoea
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 5/407 3/402 60.2 % 1.65 [ 0.40, 6.84 ]
Winikoff 2010 2/488 2/490 39.8 % 1.00 [ 0.14, 7.10 ]
Total (95% CI) 895 892 100.0 % 1.39 [ 0.44, 4.36 ]
Total events: 7 (sublingual misoprostol), 5 (IV oxytocin)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.23. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 23 Headache.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 23 Headache
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 0/407 1/402 43.1 % 0.33 [ 0.01, 8.06 ]
Winikoff 2010 3/488 2/490 56.9 % 1.51 [ 0.25, 8.97 ]
Total (95% CI) 895 892 100.0 % 1.00 [ 0.23, 4.38 ]
Total events: 3 (sublingual misoprostol), 3 (IV oxytocin)
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.24. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 24 Shivering.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 24 Shivering
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 152/407 59/402 42.0 % 2.54 [ 1.95, 3.32 ]
Winikoff 2010 229/488 82/490 58.0 % 2.80 [ 2.25, 3.49 ]
Total (95% CI) 895 892 100.0 % 2.70 [ 2.28, 3.19 ]
Total events: 381 (sublingual misoprostol), 141 (IV oxytocin)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 11.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.25. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 25 Feeling
faint or fainting.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 25 Feeling faint or fainting
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 60/407 59/402 93.7 % 1.00 [ 0.72, 1.40 ]
Winikoff 2010 4/488 4/490 6.3 % 1.00 [ 0.25, 3.99 ]
Total (95% CI) 895 892 100.0 % 1.00 [ 0.73, 1.39 ]
Total events: 64 (sublingual misoprostol), 63 (IV oxytocin)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.26. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 26 Maternal
pyrexia 38 degrees or more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 26 Maternal pyrexia 38 degrees or more
Study or subgroup
sublingual
misopros-
tol IV oxytocin
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 88/407 59/402 49.9 % 0.07 [ 0.02, 0.12 ]
Winikoff 2010 217/488 27/490 50.1 % 0.39 [ 0.34, 0.44 ]
Total (95% CI) 895 892 100.0 % 0.23 [ -0.08, 0.54 ]
Total events: 305 (sublingual misoprostol), 86 (IV oxytocin)
Heterogeneity: Tau2 = 0.05; Chi2 = 76.47, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.27. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 27 Maternal
pyrexia 40 degrees or more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 27 Maternal pyrexia 40 degrees or more
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 5/407 1/402 52.6 % 4.94 [ 0.58, 42.08 ]
Winikoff 2010 66/488 0/490 47.4 % 133.54 [ 8.29, 2151.28 ]
Total (95% CI) 895 892 100.0 % 23.54 [ 0.50, 1104.42 ]
Total events: 71 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: Tau2 = 6.13; Chi2 = 4.82, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.28. Comparison 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH
treatment among women who have not received any conventional uterotonic therapy, Outcome 28 Allergy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 2 Sublingual misoprostol versus intravenous oxytocin therapy for primary PPH treatment among women who have not received any conventional uterotonic
therapy
Outcome: 28 Allergy
Study or subgroup
sublingual
misopros-
tol IV oxytocin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg misoprostol versus 40 IU oxytocin
Blum 2010 1/407 0/402 25.2 % 2.96 [ 0.12, 72.52 ]
Winikoff 2010 0/488 1/490 74.8 % 0.33 [ 0.01, 8.20 ]
Total (95% CI) 895 892 100.0 % 1.00 [ 0.14, 7.09 ]
Total events: 1 (sublingual misoprostol), 1 (IV oxytocin)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for
primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome
1 Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any
conventional uterotonic therapy
Outcome: 1 Hysterectomy
Study or subgroup Misoprostol Oxytocin/ergometrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 800 mcg
Lokugamage 2001 0/32 1/32 100.0 % 0.33 [ 0.01, 7.89 ]
Total (95% CI) 32 32 100.0 % 0.33 [ 0.01, 7.89 ]
Total events: 0 (Misoprostol), 1 (Oxytocin/ergometrine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for
primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome
2 Persistent haemorrhage.
Review: Treatment for primary postpartum haemorrhage
Comparison: 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any
conventional uterotonic therapy
Outcome: 2 Persistent haemorrhage
Study or subgroup Misoprostol Oxytocin/ergometrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lokugamage 2001 2/32 11/32 100.0 % 0.18 [ 0.04, 0.76 ]
Total (95% CI) 32 32 100.0 % 0.18 [ 0.04, 0.76 ]
Total events: 2 (Misoprostol), 11 (Oxytocin/ergometrine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for
primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome
3 Additional uterotonics.
Review: Treatment for primary postpartum haemorrhage
Comparison: 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any
conventional uterotonic therapy
Outcome: 3 Additional uterotonics
Study or subgroup Misoprostol Oxytocin/ergometrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lokugamage 2001 2/32 11/32 100.0 % 0.18 [ 0.04, 0.76 ]
Total (95% CI) 32 32 100.0 % 0.18 [ 0.04, 0.76 ]
Total events: 2 (Misoprostol), 11 (Oxytocin/ergometrine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for
primary PPH treatment among women who have not received any conventional uterotonic therapy, Outcome
4 Surgical co-interventions (excluding hysterectomy).
Review: Treatment for primary postpartum haemorrhage
Comparison: 3 Rectal misoprostol versus combination of ergometrine and oxytocin therapy for primary PPH treatment among women who have not received any
conventional uterotonic therapy
Outcome: 4 Surgical co-interventions (excluding hysterectomy)
Study or subgroup Misoprostol Oxytocin/ergometrine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lokugamage 2001 2/32 2/32 100.0 % 1.00 [ 0.15, 6.67 ]
Total (95% CI) 32 32 100.0 % 1.00 [ 0.15, 6.67 ]
Total events: 2 (Misoprostol), 2 (Oxytocin/ergometrine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional
uterotonics for primary PPH, Outcome 1 Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 1 Hysterectomy
Study or subgroup Estrogen control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhou 2006 0/52 3/60 100.0 % 0.16 [ 0.01, 3.11 ]
Total (95% CI) 52 60 100.0 % 0.16 [ 0.01, 3.11 ]
Total events: 0 (Estrogen), 3 (control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional
uterotonics for primary PPH, Outcome 2 Mean blood loss within two hours.
Review: Treatment for primary postpartum haemorrhage
Comparison: 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 2 Mean blood loss within two hours
Study or subgroup Estrogen control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhou 2006 52 589.6 (226.4) 60 864.5 (359.5) 100.0 % -274.90 [ -384.72, -165.08 ]
Total (95% CI) 52 60 100.0 % -274.90 [ -384.72, -165.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Estrogen versus placebo/no treatment among women receiving conventional
uterotonics for primary PPH, Outcome 3 Mean blood loss between two and 24 hours.
Review: Treatment for primary postpartum haemorrhage
Comparison: 4 Estrogen versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 3 Mean blood loss between two and 24 hours
Study or subgroup Estrogen control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhou 2006 52 110.8 (76.2) 60 161.5 (98.3) 100.0 % -50.70 [ -83.07, -18.33 ]
Total (95% CI) 52 60 100.0 % -50.70 [ -83.07, -18.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours estrogen Favours control
Analysis 5.1. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 1 Maternal mortality.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 1 Maternal mortality
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 0/72 Not estimable
Total (95% CI) 72 72 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 2 Serious maternal morbidity (renal failure respiratory
failure, cardiac arrest, multiple organ failure).
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 2 Serious maternal morbidity (renal failure respiratory failure, cardiac arrest, multiple organ failure)
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 1/72 100.0 % 0.33 [ 0.01, 8.05 ]
Total (95% CI) 72 72 100.0 % 0.33 [ 0.01, 8.05 ]
Total events: 0 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 3 Admission to intensive care unit.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 3 Admission to intensive care unit
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 3/72 5/72 100.0 % 0.60 [ 0.15, 2.42 ]
Total (95% CI) 72 72 100.0 % 0.60 [ 0.15, 2.42 ]
Total events: 3 (Tranexamic acid), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 4 Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 4 Hysterectomy
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 1/72 100.0 % 0.33 [ 0.01, 8.05 ]
Total (95% CI) 72 72 100.0 % 0.33 [ 0.01, 8.05 ]
Total events: 0 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 5 Blood loss 500 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 5 Blood loss 500 mL or more after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 72/72 72/72 100.0 % 1.00 [ 0.97, 1.03 ]
Total (95% CI) 72 72 100.0 % 1.00 [ 0.97, 1.03 ]
Total events: 72 (Tranexamic acid), 72 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 6 Blood loss 1000 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 6 Blood loss 1000 mL or more after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 17/72 15/72 100.0 % 1.13 [ 0.61, 2.09 ]
Total (95% CI) 72 72 100.0 % 1.13 [ 0.61, 2.09 ]
Total events: 17 (Tranexamic acid), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 7 Total mean blood loss after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 7 Total mean blood loss after enrolment
Study or subgroup Tranexamic acid Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ducloy-Bouthors 2011 72 1319 (409) 72 1410 (510) 100.0 % -91.00 [ -242.00, 60.00 ]
Total (95% CI) 72 72 100.0 % -91.00 [ -242.00, 60.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 5.8. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 8 Blood transfusion within 24 hours.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 8 Blood transfusion within 24 hours
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 7/72 12/72 100.0 % 0.58 [ 0.24, 1.40 ]
Total (95% CI) 72 72 100.0 % 0.58 [ 0.24, 1.40 ]
Total events: 7 (Tranexamic acid), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 9 Additional uterotonics after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 9 Additional uterotonics after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 36/72 34/72 100.0 % 1.06 [ 0.76, 1.48 ]
Total (95% CI) 72 72 100.0 % 1.06 [ 0.76, 1.48 ]
Total events: 36 (Tranexamic acid), 34 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 10 Unsatisfactory response after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 10 Unsatisfactory response after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 67/72 57/72 100.0 % 1.18 [ 1.03, 1.34 ]
Total (95% CI) 72 72 100.0 % 1.18 [ 1.03, 1.34 ]
Total events: 67 (Tranexamic acid), 57 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 11 Uterine compression stitch after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 11 Uterine compression stitch after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 2/72 100.0 % 0.20 [ 0.01, 4.09 ]
Total (95% CI) 72 72 100.0 % 0.20 [ 0.01, 4.09 ]
Total events: 0 (Tranexamic acid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 12 Interventions to control bleeding for secondary
postpartum haemorrhage.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 12 Interventions to control bleeding for secondary postpartum haemorrhage
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Medical interventions to control bleeding (new subgroup)
Ducloy-Bouthors 2011 1/72 1/72 33.3 % 1.00 [ 0.06, 15.68 ]
Subtotal (95% CI) 72 72 33.3 % 1.00 [ 0.06, 15.68 ]
Total events: 1 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Surgical evacuation
Ducloy-Bouthors 2011 1/72 2/72 66.7 % 0.50 [ 0.05, 5.39 ]
Subtotal (95% CI) 72 72 66.7 % 0.50 [ 0.05, 5.39 ]
Total events: 1 (Tranexamic acid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 144 144 100.0 % 0.67 [ 0.11, 3.93 ]
Total events: 2 (Tranexamic acid), 3 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 5.13. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 13 Examination under anaesthesia.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 13 Examination under anaesthesia
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 72/72 72/72 100.0 % 1.00 [ 0.97, 1.03 ]
Total (95% CI) 72 72 100.0 % 1.00 [ 0.97, 1.03 ]
Total events: 72 (Tranexamic acid), 72 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Tranexamic acid Favours placebo
Analysis 5.14. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 14 Uterine tamponade after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 14 Uterine tamponade after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 0/72 Not estimable
Total (95% CI) 72 72 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 5.15. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 15 Artery ligation (uterine and/or hypogastric arteries)
after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 15 Artery ligation (uterine and/or hypogastric arteries) after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 1/72 100.0 % 0.33 [ 0.01, 8.05 ]
Total (95% CI) 72 72 100.0 % 0.33 [ 0.01, 8.05 ]
Total events: 0 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.16. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 16 Arterial embolisation after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 16 Arterial embolisation after enrolment
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 4/72 5/72 100.0 % 0.80 [ 0.22, 2.86 ]
Total (95% CI) 72 72 100.0 % 0.80 [ 0.22, 2.86 ]
Total events: 4 (Tranexamic acid), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 5.17. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 17 Headache.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 17 Headache
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 0/72 Not estimable
Total (95% CI) 72 72 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.18. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 18 Nausea.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 18 Nausea
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 11/72 1/72 100.0 % 11.00 [ 1.46, 82.99 ]
Total (95% CI) 72 72 100.0 % 11.00 [ 1.46, 82.99 ]
Total events: 11 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 5.19. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 19 Maternal pyrexia 38 degrees or more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 19 Maternal pyrexia 38 degrees or more
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 12/72 11/72 100.0 % 1.09 [ 0.52, 2.31 ]
Total (95% CI) 72 72 100.0 % 1.09 [ 0.52, 2.31 ]
Total events: 12 (Tranexamic acid), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 5.20. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 20 Maternal pyrexia 40 degrees or more.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 20 Maternal pyrexia 40 degrees or more
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 0/72 Not estimable
Total (95% CI) 72 72 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.21. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 21 Deep vein thrombosis.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 21 Deep vein thrombosis
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 2/72 1/72 100.0 % 2.00 [ 0.19, 21.57 ]
Total (95% CI) 72 72 100.0 % 2.00 [ 0.19, 21.57 ]
Total events: 2 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.22. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 22 Seizures.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 22 Seizures
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 0/72 Not estimable
Total (95% CI) 72 72 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.23. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 23 Dizziness.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 23 Dizziness
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 4/72 3/72 100.0 % 1.33 [ 0.31, 5.75 ]
Total (95% CI) 72 72 100.0 % 1.33 [ 0.31, 5.75 ]
Total events: 4 (Tranexamic acid), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 5.24. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 24 Phosphenes.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 24 Phosphenes
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 8/72 2/72 100.0 % 4.00 [ 0.88, 18.19 ]
Total (95% CI) 72 72 100.0 % 4.00 [ 0.88, 18.19 ]
Total events: 8 (Tranexamic acid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
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Analysis 5.25. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 25 Secondary postpartum haemorrhage.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 25 Secondary postpartum haemorrhage
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 1/72 1/72 100.0 % 1.00 [ 0.06, 15.68 ]
Total (95% CI) 72 72 100.0 % 1.00 [ 0.06, 15.68 ]
Total events: 1 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.26. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 26 Surgical evacuation for secondary postpartum
haemorrhage.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 26 Surgical evacuation for secondary postpartum haemorrhage
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 1/72 2/72 100.0 % 0.50 [ 0.05, 5.39 ]
Total (95% CI) 72 72 100.0 % 0.50 [ 0.05, 5.39 ]
Total events: 1 (Tranexamic acid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.27. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 27 Intravenous iron therapy in the puerperium.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 27 Intravenous iron therapy in the puerperium
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 24/52 18/56 100.0 % 1.44 [ 0.89, 2.32 ]
Total (95% CI) 52 56 100.0 % 1.44 [ 0.89, 2.32 ]
Total events: 24 (Tranexamic acid), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 5.28. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 28 Hospital re-admission for secondary postpartum
haemorrhage.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 28 Hospital re-admission for secondary postpartum haemorrhage
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 1/72 2/72 100.0 % 0.50 [ 0.05, 5.39 ]
Total (95% CI) 72 72 100.0 % 0.50 [ 0.05, 5.39 ]
Total events: 1 (Tranexamic acid), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.29. Comparison 5 Tranexamic acid versus placebo/no treatment among women receiving
conventional uterotonics for primary PPH, Outcome 29 Postnatal depression at day 42 postpartum.
Review: Treatment for primary postpartum haemorrhage
Comparison: 5 Tranexamic acid versus placebo/no treatment among women receiving conventional uterotonics for primary PPH
Outcome: 29 Postnatal depression at day 42 postpartum
Study or subgroup Tranexamic acid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/72 1/72 100.0 % 0.33 [ 0.01, 8.05 ]
Total (95% CI) 72 72 100.0 % 0.33 [ 0.01, 8.05 ]
Total events: 0 (Tranexamic acid), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
1 Maternal mortality.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 1 Maternal mortality
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 0/32 0/32 Not estimable
Total (95% CI) 32 32 Not estimable
Total events: 0 (Lower segment compression), 0 (No intervention)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
2 Serious maternal morbidity.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 2 Serious maternal morbidity
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 0/32 0/32 Not estimable
Total (95% CI) 32 32 Not estimable
Total events: 0 (Lower segment compression), 0 (No intervention)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
3 Hysterectomy.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 3 Hysterectomy
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 0/32 0/32 Not estimable
Total (95% CI) 32 32 Not estimable
Total events: 0 (Lower segment compression), 0 (No intervention)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours compression Favours no compression
128Treatment for primary postpartum haemorrhage (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
4 Blood loss 500 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 4 Blood loss 500 mL or more after enrolment
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 1/32 8/32 100.0 % 0.13 [ 0.02, 0.94 ]
Total (95% CI) 32 32 100.0 % 0.13 [ 0.02, 0.94 ]
Total events: 1 (Lower segment compression), 8 (No intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
5 Blood loss 1000 mL or more after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 5 Blood loss 1000 mL or more after enrolment
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 0/32 2/32 100.0 % 0.20 [ 0.01, 4.01 ]
Total (95% CI) 32 32 100.0 % 0.20 [ 0.01, 4.01 ]
Total events: 0 (Lower segment compression), 2 (No intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
6 Average blood loss after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 6 Average blood loss after enrolment
Study or subgroup
Lower
segment
compression No intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chantrapitak 2009 32 120 (211) 32 225 (401) 100.0 % -105.00 [ -262.00, 52.00 ]
Total (95% CI) 32 32 100.0 % -105.00 [ -262.00, 52.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
7 Blood transfusion.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 7 Blood transfusion
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 7/32 3/32 100.0 % 2.33 [ 0.66, 8.23 ]
Total (95% CI) 32 32 100.0 % 2.33 [ 0.66, 8.23 ]
Total events: 7 (Lower segment compression), 3 (No intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
8 Other surgical interventions to control bleeding (other than hysterectomy).
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 8 Other surgical interventions to control bleeding (other than hysterectomy)
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 0/32 0/32 Not estimable
Total (95% CI) 32 32 Not estimable
Total events: 0 (Lower segment compression), 0 (No intervention)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Lower uterine segment compression versus conventional treatment, Outcome
9 Unsatisfactory response after enrolment.
Review: Treatment for primary postpartum haemorrhage
Comparison: 6 Lower uterine segment compression versus conventional treatment
Outcome: 9 Unsatisfactory response after enrolment
Study or subgroup
Lower
segment
compression No intervention Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chantrapitak 2009 2/32 2/32 100.0 % 1.00 [ 0.15, 6.67 ]
Total (95% CI) 32 32 100.0 % 1.00 [ 0.15, 6.67 ]
Total events: 2 (Lower segment compression), 2 (No intervention)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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WH A T ’ S N E W
Last assessed as up-to-date: 31 August 2013.
Date Event Description
31 August 2013 New search has been performed Search updated (31 August 2013). Seven new studies in-
corporated into review (Blum 2010; Chantrapitak 2009;
Ducloy-Bouthors 2011; Widmer 2010; Winikoff 2010;
Zhou 2006; Zuberi 2008). One study awaiting classi-
fication (Lavigne-Lissalde 2013), and five studies ongo-
ing (Collins 2013; Miller 2008; Mirzazada 2011; Shakur
2010; Wikkelsoe 2012). Methods updated.
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(Continued)
31 August 2013 New citation required and conclusions have changed Additional data fromnew studies now suggest that in com-
parison with oxytocin, women given sublingual misopros-
tol are more likely to have greater blood loss
For other outcomes, the conclusions remain the same:
misoprostol in comparison with placebo has no impact
on maternal mortality, maternal morbidity, hysterectomy,
and admission to intensive care; sublingual misoprostol
in comparison with oxytocin increases the likelihood of
adverse effects such as vomiting and shivering
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 1, 2003
Date Event Description
8 May 2008 Amended Converted to new review format.
14 November 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Hatem Mousa assessed trial eligibility, extracted the data and co-wrote the review.
Jennifer Blum provided data of published trials and co-wrote the review.
Ghada Abou El Senoun assessed trial eligibility, entered data and co-wrote the review.
Haleema Shakur assessed trial eligibility and co-wrote the review.
Zarko Alfirevic verified trial eligibility, extracted data and co-wrote the review.
D E C L A R A T I O N S O F I N T E R E S T
Haleema Shakur andZarkoAlfirevic are investigators in the currently ongoingWOMAN trial. Jennifer Blumwas a principal investigator
in the Blum 2010, Winikoff 2010, Widmer 2010 and Zuberi 2008 trials. Hatem Mousa has received financial support from Novo
Nordisk to investigate recombinant activated factor VII (rFVIIa) as a potential treatment for massive postpartum haemorrhage.
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S O U R C E S O F S U P P O R T
Internal sources
• The University of Liverpool, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Methods updated.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Rectal; Ergonovine [administration & dosage]; Hysterectomy; Maternal Mortality; Misoprostol [administration &
dosage]; Oxytocics [administration & dosage]; Oxytocin [administration & dosage]; Postpartum Hemorrhage [drug therapy; surgery;
∗therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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